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Kirk A. Unger and James H. Watterson 
Dextromethorphan and its Metabolites in Rat Bone Tissues by Gas Chromatography Mass 
Spectrometry Analysis Following Differential Microclimate Decomposition 
ABSTRACT:  
The effect of microclimate on dextromethorphan (DXM) and dextrorphan (DXT) responses in 
skeletonized rat remains was examined.  Animals (n=10) received dextromethorphan at 75 mg/kg 
by i.p. injection for comparison against drug-free controls (n=4), and across different 
decomposition sites.  Rats were divided equally into two groups and placed at different sites for 
decomposition immediately following euthanasia (30 minutes post dose).  Rats at Site A 
decomposed in a shaded forest microenvironment on a grass-covered soil substrate.  Site B animals 
rested on rock and gravel substrate exposed to open air and direct sunlight.  Site A and Site B are 
approximately 600 m apart.  Ambient temperature and relative humidity measurements recorded 
by data loggers mounted 3 cm above rats at each site established microclimate differences.  Bone 
elements (vertebrae, ribs, pelvic girdles, femora, tibiae, humeri and scapulae) were harvested, 
cleaned and pulverized for Microwave Assisted Extraction in methanol.  Drug and metabolite 
extractions were isolated by solid phase extraction prior to GC/MS analyses.  Mass normalized 
DXM and DXT levels and metabolite/drug ratios were compared across different bone elements 
(within and between animals) and microclimate sites.  Concentrations calculated from drug 
responses and standard curve plots gave estimated concentrations of 399 to 10,474 ng/g for DXM 
and 132 to 3,668 ng/g for DXT.  Max/min values across animals and bone elements examined 
response variation.  No significant differences in DXT levels or metabolite/parent ratios were 
observed between sites or across different bone elements.  The only significant difference for DXM 
levels were found in femurs compared across microclimate sites.  Microclimate showed no 
significant influence on observed DXM or DXT values, indicating bone as a drug reservoir may 
behave uniformly for certain drugs across different environments of decomposition.  The results 
of this study show limited agreement with previous work from our laboratory on drug recoveries 
from decomposed bone tissues. 
KEYWORDS: Blood, Decomposed Bone, Dextromethorphan, Dextrorphan, Forensic 
Toxicology, GC/MS, Microclimate, MAE, SPE.  
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
1.1 Introduction 
 Toxicological analysis of bone tissue may be considered in cases of advanced 
decomposition or post-mortem manipulation of remains where blood or other tissues and fluids 
are not present or degraded beyond toxicological use.  Toxicological analysis of human bone has 
been performed in cases of work-place or environmental exposure to toxins (1–4) and for drugs in 
a number of forensic cases (5–8) using a variety of bone tissues and analyses.  Though drug 
detection in post-mortem bone tissues is possible, interpretation of drug-in-bone analysis is 
difficult given the number of factors that determine drug deposition in bone and dearth of research 
and casework (8).  Recent studies from our laboratory and others have measured drug exposure in 
bone using animal models and have established differences in drug distributions within bone 
elements, between acute vs. repeated doses and by environment of decomposition (9–18).  Only 
one study has compared drug responses in bone after surficial decomposition across different 
microclimate environments (18) by gas chromatography-mass spectrometry (GC/MS) analysis for 
ketamine and metabolites.  Environmental conditions have been shown to control the rate and 
degree of decomposition which influences and is reflected by the degree of insect activity , the 
production of putrefaction products (19) and extent of bioerosion of bone tissues by 
microorganisms (20), the effects of climate on drugs in bone following advanced surficial 
decomposition is largely unknown.       
1.2 Drug Detection in Skeletal Tissues 
 Drugs and their metabolites have been detected in human bone tissues using various 
methods of extraction.  Amitriptyline (5) was detected by GC/MS analysis in vertebral marrow 
following extraction by warm ethanol and a series of liquid-liquid extractions (LLE).  GC/MS 
 
 
2 
 
detection of methamphetamine followed LLE and SPE treatment of ethyl ether extraction from 
femoral marrow (6).  GC/MS instrumentation detected triazolam in femoral marrow following 
digestion in 2M sodium hydroxide, extraction in tert-butyl methyl ether and a series of LLE (21).  
Citalopram was extracted from iliac crest sections by soaking the bone in methanol and was 
isolated by LLE prior to GC/MS analysis (22).  A broader study demonstrated a number of 
forensically relevant drugs and their metabolites (amitriptyline, citalopram, meperidine, 
oxycodone, diazepam, codeine, cocaine and others) can be detected in bone tissues by GC/MS 
using a methanolic extraction (8).  This study also compared bone responses to blood and found 
no appreciable relationship, though chronic exposure was speculated to lead to the presence of 
drug in bone tissues, especially where none was present in blood (8).   
 The stability of a given drug in post-mortem tissues is an important factor to be considered, 
and sample selection should be done with this in mind.  Though bone tissues offer the potential 
for qualitative analyses, post-mortem drug redistribution and stability, among a number of other 
factors, make the interpretation and quantification of post-mortem analyses of drugs in bone 
complicated and challenging (23).  A study in the temporal fate of drugs in pig remains showed 
drug concentrations in soft tissues increased as tissues decomposed (24); maggots feeding on the 
remains were shown to have detectable levels of drugs within a few days and remained detectable 
in soil below the carcass for up to 2 years (24).  Though this study did not analyze bone tissues, 
the results show that lipid or water solubility of the drugs may play important roles in drug 
distribution within remains that are exposed to surficial decomposition environments (24).   
Because no clear relationship between drug-in-bone and blood concentration has been 
established, controlled experiments using animal models have explored bone tissues as a repository 
for drugs of forensic interest.  Drug-in-bone interpretation is made even less clear because of the 
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lack of standardized methods used for the analysis of a given drug in bone tissue.  The use of 
animal models allows for comparison of drugs, metabolites, doses, dose-death intervals and the 
time and environments of decomposition and can be used to establish standardized methods for 
drug-bone analysis and patterns useful in interpreting post-mortem drug-in-bone toxicological 
results. 
1.3 Drugs in Animal Bone Tissues 
Animal studies have shown bone tissues may be useful reservoirs for forensically relevant 
drugs across a number of bone tissue types, bone elements and ranges of post-mortem 
environments (10, 11, 13–18, 22).  However, as in the above human bone analyses, methods can 
vary across animal model studies and lack standardization.  Part of the work in our laboratory has 
been to establish consistent methods of analysis going towards a standardized way of analyzing 
animal bone tissues for drugs and metabolites.   
 Attempts to correlate drug concentrations in blood or plasma to those in bone have been 
made using animal studies.  Desipramine in femoral and tibial marrow following repeated oral 
administration in rabbits was shown to be a good indicator of plasma concentration of the drug 90 
minutes post-dose by High Performance Liquid Chromatography (HPLC) analysis (25).  This 
study showed the potential of marrow as a suitable matrix for tricyclic antidepressant analysis in 
the absence of blood, however the timeframe of this study precludes such interpretations in cases 
of advanced decomposition where drug and marrow stability in bone matrices have serious 
questions to be addressed.   
Morphine from rabbit marrow following intravenous (IV) injection was analyzed by 
immunoassay following 7 and 14 days of burial post dose for comparison to marrow, blood and 
urine morphine concentration and showed good correlation with perimortem blood-marrow opioid 
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levels even as the measured response of the drug in marrow decreased roughly 50% over the 14 
day period (13).  This study showed drug and/or marrow stability may influence recovered drug 
in marrow, and though blood-marrow correlation following burial was significant, though the 
study is limited by immunoassay techniques and further research using statistically valid numbers 
of samples and quantitative analytical methods is necessary.   
 In a study analyzing post-mortem morphine by GC/MS in mouse tissues, no such 
correlation between marrow-blood concentrations could be determined (26).  This study compared 
repeated and acute doses of morphine in a variety of mouse tissues, and showed that the 
lipophilicity of the drug may influence post-mortem distribution, and that drug levels in bone 
following chronic vs. acute exposures can vary significantly (26).  The stability of morphine in 
skeletal tissues was also shown to be a problem and was measured only below the Limit of 
Quantification (LOQ) after storage in soil after 2 months; though a blood-marrow correlation may 
exist, it was not shown in this study (26).  Determining if a given exposure followed repeated 
morphine dosing could not be determined from the analysis of skeletal tissues, though an acute 
lethal dose might be detected (23).  The results of this study go to illustrating the difficulties of 
interpreting post-mortem drug analysis from bone tissues.  Metabolism can vary across species 
and individuals (27, 28), which effects the levels of certain metabolites used to quantify drugs in 
toxicological analyses.  The route of administration (27) and chemical properties of the drugs will 
affect the uptake of the compound by bone tissues (29), the environment and position of the 
remains during post-mortem decomposition can influence the presence of drugs in individual bone 
elements (14, 17, 18, 30) and the paucity of research and lack of standardized methods make 
interpretation of drug-bone levels a risky prospect at best. 
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 The inability to accurately quantify drug in bone tissues to doses or perimortem blood 
concentrations has led to different methods of toxicological study of bone tissues.  In our 
laboratory, Watterson and colleagues have used mass-normalized response ratios (RR/m) and 
parent drug-metabolite ratios to investigate relative drug distribution across skeletal elements in 
order to assess the effects of repeated and acute doses and environments of decomposition (9, 11, 
14, 16–18, 31).   
A study of amitriptyline, citalopram, diazepam, morphine and pentobarbital in porcine 
skeletal tissues found that skeletal element type was a main effect of drug levels, with rib, femoral, 
vertebral and pelvic girdle tissues having the highest RR/m drug levels (16).  The use of RR/m 
addresses the inability to accurately quantify drug concentrations in bone tissues since the sample 
matrix is a heterogeneous material and analyte recovery cannot be definitively quantified using 
techniques standard to forensic toxicology.  The higher drug level in central cavity bones may 
indicate post-mortem redistribution from surrounding organs and tissues, illustrating the limits of 
interpretation of drug levels in bone given varying responses  skeletal elements (16).   
 Ketamine distribution in rats across different sections of bone (marrow, epiphyseal and 
diaphyseal) by ELISA and GC/MS analysis were compared across burial environments (17).  The 
results of this study indicated the recovery of ketamine is both bone tissue and burial dependent 
(17).  This goes to showing the influence of the local environment on the recovery of drugs in bone 
tissues. 
 The value of parent-metabolite ratios was introduced in a study that used SPE and GC/MS 
to analyze amitriptyline and citalopram in porcine bone tissues following outdoor decomposition 
(12).  A high variability of parent drug levels were again across bone elements, though the ratio of 
levels of parent drug to those of their metabolites were less variable (12), indicating forensic 
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potential in investigating the levels of both metabolites and drugs in bone tissues.  Another study 
(14) established the value of parent-metabolite ratios in comparison in rat skeletal tissues by SPE 
and GC/MS analyses for acute and repeated doses of amitriptyline and citalopram.  Ratios between 
parent and metabolite compounds varied across repeated and acute exposure types, indicating a 
pattern of drug use may be distinguished in bone analyses following advanced decomposition (14).   
 The effect of body position and microclimate was explored in rats given acute doses of 
ketamine in two different microclimate environments (18).  Ketamine and its metabolites were 
analyzed for by GC/MS in different bone elements.  The results of the study showed an influence 
of body position and the surficial microclimate environment during decomposition on the RR/m 
of the parent drug, metabolites and parent-metabolite ratios in different skeletal elements (18).  
This study illustrates the difficulty of interpreting toxicological analysis of bone by introducing a 
new factor to consider. 
 The work of Watterson and colleagues has continued to develop methods for the analysis 
of forensically relevant drugs.  A recent study investigated DXM and DXT in decomposed rat 
bone tissues (9) presents a method for assay using MAE, SPE and GC/MS for DXM and DXT 
analysis and established the stability of the compounds in both microwave extraction and in bone 
after decomposition.  The methods from this paper (9) were used to develop the extraction and 
analytical techniques used in the current study.     
1.4 Dextromethorphan and its Metabolites 
 Dextromethorphan is primarily known for its cough-supressing antitussive effect, and is the 
“DM” in many brand over the counter cough syrups.  Cough supressing effects are present at 
therapeutic doses of 30 to 60 mg of DXM.  Experimental uses of DXM have been to test for the 
treatment of Huntington’s disease (32), Parkinson’s disease (33), complex partial seizures (34) as 
 
 
7 
 
doses of DXM higher than antitussive treatments has shown to have neuroprotective and 
anticonvulsant properties (35–37).  Blood concentrations associated with abuse for DXM are in 
excess of 200 mg with dissociative hallucinogenic effects similar to phencyclidine (PCP), which 
may seriously limit therapeutic use (27).  Reported effects of DXM abuse are euphoria, 
hallucinations, perceptual alterations, aggressive behavior, nausea and drunkenness (27, 38).  
Abuse of DXM has been reported in the literature as early as 1964 (39) and fatal overdoses have 
been reported (40–42).  Post-mortem blood concentrations of DXM associated fatalities ranged 
from 950 to 3230 ng/mL in 5 deaths, well above reported therapeutic plasma concentrations of 10 
to 40 ng/ mL (42, 43).  Post-mortem redistribution of DXM in blood is reported, the interpretation 
of toxic levels of DXM should take the location of post-mortem blood samples into account.  
Central to peripheral blood ratios of DXM levels from 5 post-mortem cases ranged from 1.0 to 
3.5, with volumes of distribution (Vd) of 5.0 to 6.4 L/kg (44).  Post-mortem redistribution of drugs 
may be a factor influencing the degree drugs partition into bone tissues and should be considered 
when investigating drug in bone concentrations. 
 The major metabolite of DXM, dextrorphan (DXT), has been shown to have 
pharmacological effects similar to PCP at high doses and may be a prodrug that produces 
dissociative hallucination effects.  The prodrug nature of DXM and has been indicated by a number 
of studies in animals (45–47), some indicating DXM offers no PCP-like effects (48).  The route of 
administration and the metabolic rates of individuals will therefore influence the degree of DXM 
to DXT conversion and the desired effects of DXM abuse (27).  Since DXM is primarily 
metabolized by the cytochrome enzyme CYP2D6 (27), phenotypic discrimination between fast 
and slow metabolizers has been investigated using post-mortem ratios of DXM and DXT (28).  
The metabolic pathway of DXM is presented in Figure 1.1.  
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Figure 1.1: Metabolic pathway of dextromethorphan to secondary metabolite 3-hydroxymorphinan 
(dmDXT) from first metabolites dextrorphan (DXT) or 3-methoxymorphinan from demethylation 
by liver cytochrome (CYP) enzyme action. 
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 Dextrorphan shares similar antitussive and neuroprotective effects with DXM (27).  Unlike 
its parent drug, DXT has been shown to have a high affinity for PCP receptor cites in rat brains, 
which may account for the PCP-like behaviours in animals given DXT (48–50).  DXT, like PCP 
and ketamine, acts as a non-competitive antagonist on N-methyl-D-aspartate (NMDA) receptors, 
inhibiting ion-channel protein function in nerve cells (51).  A corresponding rise in extracellular 
glutamate concentrations in the prefrontal cortex of rat brains has been seen at sub-anesthetic doses 
of non-competitive NMDA antagonists like ketamine (52).  The rise in prefrontal glutamate 
concentrations and prefrontal activity in humans has also been seen in other more widely used 
hallucinogens like psilocybin, along with ketamine and with high doses of DXM (52, 53), the 
NMDA antagonist function of the latter may largely be due to its active metabolite DXT (27, 45, 
48, 50).   
Because of the active metabolite nature of DXT and extensive first pass metabolism of 
DXM by CYP liver enzymes (27), the route of administration (RoA) of DXM will affect the time 
course and free DXT concentrations.  DXM and DXT in rat plasma and brain tissues following 
different routes of administration were compared using HPLC methods; maximum concentrations 
(Cmax) of DXT in brain tissues and plasma were 5 and 12 times higher in intraperitoneal injection 
than for subcutaneous (SC) injections (27).  Free DXM concentrations were higher following SC, 
the differences in DXM and DXT concentrations in plasma and brain tissues is attributed to the 
extensive first pass metabolism afforded to IP injections (27).  Along with route of administration, 
the CYP2D6 phenotype should also be considered when investigating DXM or DXT 
concentrations in human samples.  Given the Cmax of DXT will favor a RoA that allows for first 
pass metabolism of DXM, the minority of humans with CYP2D6 gene deletions or mutations will 
have lower DXT concentrations and higher DXM levels following administration of DXM (27, 
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28).  Studies looking into DXM metabolism and behavioral effects should consider CYP2D6 
phenotypes and RoA as they will determine the Cmax and time course of DXM and the prodrug 
DXT. 
1.5 Microwave Assisted Extraction 
 Microwave Assisted Extraction (MAE) is an efficient, effective and rapid way of extracting 
a number of compounds from a variety of matrices, including drug from bone (9, 15, 54–59).  
Microwave energy is non-ionizing electromagnetic radiation that at 2450 MHz, heats the irradiated 
materials by the rotation and agitation of polar molecules (59).  Microwave heating is also volumic, 
heating the entire mass of reactant and the solvent even above theoretical solvent boiling points 
under closed systems, the latter better facilitates analyte extraction (57, 59).  Microwave energy 
can selectively heat chemical species while simultaneously breaking down microstructures of 
sample matrices to release targeted analytes, and since many organic solvents absorb microwave 
energy to lesser extents than many compounds, organic solvents serve to effectively cool and 
solvate targeted compounds (54, 58).   
Since its inception, MAE has offered a number of advantages over previous extraction 
methods including significant reduction in extraction time, reduced solvent use, increased number 
of sample extractions, improved yield of extracted analytes, automation and improved precision, 
tailored methods for specific compounds and matrices, and constant sample agitation throughout 
extraction (54, 57, 59).  Though MAE methods are useful for extraction of many organic 
compounds, the stability of desired analytes and the appropriate solvents used must be validated 
prior to use in toxicological studies.  The stability of DXM and DXT under MAE conditions was 
established in previously published work and the extraction of DXM, DXT and dmDXT in this 
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study follow those from previously published drug from bone MAE extraction methods (9, 15, 18, 
55).   
1.6 Gas Chromatography and Mass Spectrometry 
 Chromatography is a method of separating chemical compounds in a sample; gas 
chromatography is the separation of organic volatile compounds (VOCs) (60).  Compounds are 
separated by chemical interactions with immiscible stationary and mobile phases.  Different 
compounds will react differently with the stationary phase.  Compounds with a high affinity for 
stationary phase interactions will lag behind compounds with lower affinity for the stationary 
phase.  The degree a compound interacts with the stationary phase compared to its concentration 
in the mobile phase is known as the distribution coefficient, or Kd.  For a given compound, different 
mobile and stationary phases will affect the compounds Kd, so for compounds of interest, the 
choices of stationary and mobile phases used in chromatography should be made with optimal 
analyte separation in mind. 
 Gas chromatography uses the above principles of distribution to achieve analyte resolution.  
A mixture of a number of compounds is carried in a gas mobile phase over a stationary liquid film 
or gel phase lining the inside of a column which separates the compounds by differing Kd (61).  
The GC method has proven to be an accurate method of compositional analyses for a number of 
fields including petroleum, pharmaceutical and chemical industries, biochemical research, forensic 
sciences and even food and flavour studies (61).  The heart of the GC method is the column.  The 
degree of compound separation, and thereby the full resolution of endogenous compounds and 
analytes, can be determined solely the column used (61).  Today fused-silica columns are the 
standard capillaries used in GC methods (60).  Silica lining the inside of capillaries is treated by 
high temperature silylation, a method that renders active silica sites chemically inert and allows 
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for more uniform lining by stationary phase films (62).  Analyte resolution can also be helped by 
narrowing the capillary used in GC and increasing the temperature through the run to improve 
compound volatility, especially for those eluting later (61).   
 Some compounds are not amenable to GC as reactive groups can impair volatility and 
increase interactions with the stationary phase.  Polar groups with active hydrogen sites, like amine 
and hydroxyl groups, will perform poorly in the column and peak width spreading and tailing may 
be seen, reducing compound resolution impairing interpretation of GC analysis (63).  An additional 
step during sample preparation replaces active sites with an unreactive group that will improve 
volatility, and therefore GC performance, especially for small molecules with inter-molecule polar 
interactions, such as carboxyl acids, phenols, alcohols and other reactive groups (64).  
Derivatization can be completed with acylation and alkylation, but most commonly silylation, 
where the active hydrogen on the substrate is replaced by a silyl group, generally trimethylsilyl 
(64).  A generalized silylation derivatization reaction of DXT is presented in Figure 1.2. Silylation 
proceeds by SN2 mechanism (64) where the analyte acts as the nucleophile.  Derivatization agents 
are manufactured with the derivatizing group are bound to a good leaving group.  The resulting 
product is a new “derivatized” compound with improved GC performance that is amenable in a 
variety of column types and analytical conditions (63).   
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Figure 1.2: Reactants and products of the derivatization reaction of DXT with N-methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA).  The active hydrogen of the 3-hydroxyl group on 
DXT is silylated to improve resolution in GC capillaries by reducing capillary wall interactions. 
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 The separation of compounds within a mixture by GC is well established, but separation of 
an analyte from a sample mixture is not enough for compound identification.  A detector 
instrument must be used to identify compounds as they elute from the GC column.  Mass 
spectrometry (MS) is a useful tool in forensic toxicology as MS methods generate reproducible, 
standardized results for a given compound across a wide variety of analytical conditions (63).  
Compounds separated by GC elute from the column into a MS instrument that can provide 
qualitative and quantitative detection of analytes (63).  In GC/MS, compounds that elute from the 
capillary are ionized and fragmented by electron bombardment.  The ionized molecules and 
fragments are sorted by molecular weight, or “mass to charge ratio” (m/z) by (quadrupole) mass 
analyzer instrumentation (61).  For a given ionization energy, a molecule will ionize and fragment, 
creating a diagnostic mass spectrum, allowing for identification of the resolved analyte eluting 
from the GC capillary (63).  The quadrupole instrument can isolate ions of specific m/z by 
changing voltages across the four poles of the instrument which generates oscillating radio 
frequency currents that permit all (full scan, or FS) or desired (selected ion monitoring, or SIM) 
ions to be detected (63) by the MS instrument.  Using SIM mode for MS analysis allows for the 
user to measure specific diagnostic ions which imparts greater sensitivity by increasing the 
detection time for diagnostic ions and reducing signal noise from undesired ions that reach the 
detector (61).  Mass spectra of an analyte, be it from FS or SIM modes, can be compared to known 
standards or a library of mass spectra for identification (61, 63).   
1.7 Environmental Factors and Microclimate Conditions during Decomposition 
 The environment of decomposition has been shown to influence drug stability and therefore 
recovery in animal bone tissues (17, 18), though environmental data has not been collected during 
these studies.  Microclimate conditions have been shown to influence the rate of putrefaction 
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product formation during decomposition of human remains, with temperature as a driving factor 
in chemical reaction rates (19).  Temperature is thought to be the predominant factor in determining 
the rate of decomposition and several methods using accumulated degree-days are used to estimate 
post-mortem intervals, or PMI, where intervals are corrected to an average temperature interval 
period (65, 66).  Moisture levels are also important controls in the rates and degrees of 
decomposition, as extremely dry conditions will lead to the desiccation of tissues, inhibit microbial 
action and exclude important insect or other carrion activity.  When water is present, attributes 
associated with water that influence decomposition are “(a) a high specific heat that stabilizes 
temperatures; (b) buffering capacity that moderates the effects of local pH changes; (c) sources of 
hydrogen required for numerous biochemical reactions; (d) its effect as a diluent; and (e) its ability 
to act as a solvent for polar molecules (67)”.  Environment pH, partial pressure of oxygen and 
temperature are also important factors that influence the rate of decay (67).  Significant variation 
in environmental data has been observed across microclimatic sites, even over small distances, and 
the use of regional weather data for PMI calculations should be done so with caution (68). 
 Energy exchange in the environment is has largely been overlooked in forensic research of 
decomposing bodies.  A body in direct sunlight can receive in excess of 2 calories per cm2 per 
minute of energy (a value that will change with increasing or decreasing latitude) and upwards of 
0.76 cal/cm2/min from surface substrate radiating as a black body, even at night (69).  This energy 
flux will affect chemical and molecular rates and stability, evaporation of water and volatiles and 
other biological processes that may influence drug and metabolite stability in decomposing tissues 
across a variety of environments and shelters.  Clearly, there are a number of factors that will 
influence the stability and therefore recovery of drug from bone tissues.  There is a lack of research 
investigating the role of microclimate on post-mortem drug stability.  Microclimatic factors, if 
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established as an influence on post-mortem drug stability and differential tissue 
compartmentalization shouldn’t be solely related to outdoor environments of decomposition.  
Cases of advanced decomposition from outdoor environs are not the typical workload of forensic 
toxicologists, advanced putrefaction can be found in cases of advanced decay within dwellings 
where a person has been dead for a number of days or weeks prior to discovery.  The temperature 
and moisture surrounding the deceased, regardless of environment will play a role in the rates of 
putrefaction products, entomological activity, rates of decay and analyte stability.  To date no 
catalog of these factors on bone tissue analyses has been developed. 
1.8 Goals of Study 
 Dextromethorphan (DXM) and metabolites dextrorphan (DXT) and 3-hydroxymorphinan 
(dmDXT) were recovered from bone elements from rats given acute doses of DXM following 
differential microclimate decomposition using Microwave Assisted Extraction (MAE), Solid 
Phase Extraction (SPE) and GC/MS.  Rats were divided into two groups to compare observed drug 
levels across different microclimate sites to investigate climate effects on DXM and metabolite 
levels following decomposition as little is known about environmental effects on drug stability and 
the effect on bone as a matrix for drug retention, and that differences were observed following a 
similar study using ketamine (18).  Temperature and relative humidity (RH%) data was recorded 
at each site throughout the study to establish different microclimatic conditions.  
The objective of this study is to determine if microclimatic conditions during 
decomposition can be discriminated in dextromethorphan and its metabolites in post-mortem bone 
tissues.  Patterns of parent-metabolite ratios have been shown to be different in ketamine analyses 
across different microclimates (18), aid in the discrimination of repeated or acute drug doses (12, 
14) and may reflect drug-metabolite stability across microclimates.  In this study, unlike the 
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ketamine study, environmental data was logged remotely at both decomposition sites and 
compared to regional climate data. Dextromethorphan was administered by i.p. injection to rats at 
a dose of 75mg/kg and were euthanized by CO2 asphyxiation.  Rats (n=10) were divided across 
two microclimate sites, 5 rats were placed outside in a temperate forest with grass and soil 
substrate, the other 5 were placed on an exposed rock barren with gravel substrate; both sites are 
located on the Laurentian University campus in Sudbury, Ontario.  Levels of DXM and DXT were 
measured using GC/MS with silylation derivatization and corrected for sample masses.  Parent to 
metabolite ratios were calculated to determine possible site discrimination for individual elements 
or pooled bone results.   
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Drug Standards 
 Dextromethorphan and dextrorphan drug standards, and corresponding deuterated internal 
standards were obtained from Cerilliant Corporation (Round Rock, TX).  DXM and DXT drug 
standards were diluted from 1 mL methanolic solutions at concentrations of 1 mg/mL.  Deuterated 
internal drug standards d3-DXM and d3-DXT were diluted from 100 ug/mL methanolic solutions.  
3-methoxymorphinan (dmDXT) was provided by Toronto Research Chemicals (Toronto, ON) in 
1 mg powder form and was diluted as needed.  No deuterated internal standard for dmDXT was 
available at the time of study. 
2.2 Chemicals 
 Reagent grade chemicals were used in this study.  Acetonitrile (ACN), isopropanol (ISO), 
and glacial acetic acid (GAA) were obtained from BDH/VWR Analytical (Radnor, PA).  
Ammonium hydroxide (NH4OH) and methanol (MeOH) were supplied by Fisher Chemicals 
(Pittsburgh, PA).  Ethyl acetate (EA) was provided by EMD Chemicals (Gibbstown, NJ).  
Anhydrous sodium monophosphate was obtained from Amresco LLC (Solon, OH).  Selectra-Sil® 
N-methyl-N-(trimethylsilyl) trifluoroacetamide with 1% trimethylchlorosilane derivatization 
agent (MSTFA+1%TMCS) was purchased from United Chemical Technologies (Bristol, PA). 
2.3 Animal Care and Drug Administration 
All procedures during the course of this study were in compliance with the Laurentian 
University Animal Care Committee.  Fourteen adult male Sprague-Dawley® rats were provided 
by Charles River Laboratories (Saint-Constant, QC).  Live rats were housed and handled at the 
Laurentian University Animal Care Facility on a 12 hour light/dark cycle and supplied water and 
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Harlan Teklad Laboratory Diet 8640 (Indianapolis, IN) with no set feeding schedule.  Ten rats 
were given single intraperitoneal (i.p.) injections of DXM at 75 mg/kg and 4 remained drug-free 
to serve as control animals for this study.  Animals were euthanized by CO2 asphyxiation 30 
minutes after DXM administration.   
Heart blood was taken perimortem from all rats with the exception of Animal ACU A4, 
which died prior to blood sampling and asphyxiation.  Blood was stored in 4 mL BD Vacutainer® 
tubes with 10 mg sodium fluoride and 8 mg potassium oxalate anticoagulants from BD Diagnostics 
(Franklin Lakes, NJ).  Blood samples were stored at 4°C prior to analysis. 
Euthanized animals were divided across two microclimate decomposition sites, 5 drug 
positive animals were placed at Site A (ACU A1-A5) and 5 drug positive animals were placed at 
Site B (ACU B1-B5).  Site A is a shaded forest site with soil and grassy substrate.  Site B is an 
exposed rock barren site with gravel substrate.  Animals were enclosed in wooden framed 1/2” 
welded wire mesh cages.  Wire mesh was purchased from Home Depot (Sudbury, ON) and 1/2” 
mesh was selected to permit access to the rats by necrophagous insects and to prevent scavenging 
from larger animals.  Ambient microclimate measurements 3 cm above the rats were recorded 
hourly by HOBO® H08-32-IS data loggers from Onset Computer Corporation (Bourne, MA) on 
the underside of white plywood panels mounted above animals A3 and B3.  Sites A and B both 
received 2 control animals which were similarly secured with 1/2” wire mesh 3 m away from drug 
positive animals.  Rats decomposed from July 7th to July 30th, 2015.  Animal remains were 
collected individually in aluminum foil wrap prior to dissection.  Control animals were collected 
from both sites first to prevent downstream contamination from drug-positive animals. 
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2.4 Validation Bone Extract Preparation 
 Methods used in this study followed those previously published (9).  Rat bone extract used 
in method validation was prepared from the remains of decomposed drug-free animals that were 
allowed to decompose until skeletonized on the Laurentian University campus in Sudbury, ON.  
Rats were covered with welded wire mesh to prevent scavenging from animals.  Rat remains were 
collected and dissected for bone tissues.  The following bone elements were collected from each 
animal: skull, vertebrae, ulnae, radii, humeri, ribs, pelvic girdles, femora, scapulae and tibiae.  
Tweezers and scalpels were used to remove any remaining soft tissues from the bone elements.  
Bones were washed with a 0.1M phosphate buffer solution at pH of 6 (PBS), MeOH and ACN to 
remove surface contaminants.  PBS was prepared with a SB70P SympHony pH meter (VWR 
Analytical, Radnor, PA).  Washed bone elements dried for a minimum of 24 hours prior to grinding 
using a Micro-Mill® Grinder from Bel-Art SP Science Ware (Wayne, NJ) followed by 
pulverization using a 5100 Mixer/Mill® from SPEX® SamplePrep, LLC (Metuchen, NJ). 
 Pulverized bone tissues underwent microwave assisted extraction (MAE) in MeOH using 
a MARS6 Microwave Reaction System and MARS Xpress™ 25 mL PTFE reaction vessels from 
CEM Corporation (Matthews, NC) at 70°C for 30 minutes.  The solvent was pipetted from the 
reaction vessels in 5 mL volumes into 13-100 mm Fisherbrand Borosilicate test tubes (Pittsburgh, 
PA), and were evaporated to dryness under vacuum using an Acid Resistant CentriVap® 
Concentrator and -50°C CentriVap® Cold Trap (Labconco, Kansas City, MO).  The dried 
constituents of each test tube were reconstituted and vortexed with 1 mL of PBS using a VX-200 
Vortex Mixer from Labnet International (Edison, NJ) and then pooled for method validation 
analyses. 
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2.5 Validation Sample Preparation 
 Standard curves with nine triplicate concentrations of DXM, DXT and dmDXT ranging 
from 0-2000 ng/ mL were prepared for GC/MS analysis in 1 mL volumes of bone tissue extract 
prepared as above.  All samples received 200 ng of d3-DXM and d3-DXT internal standards.  
Samples and dilutions were prepared to desired concentrations using 5-50 μL, 20-200 μL and 100-
1000 μL Signature Ergonomic High Performance Pipettors from VWR Analytical.  This method 
is used as a best approximation of drug recovery from bone tissues as it is impossible to impregnate 
a skeleton or single skeletal element, be it from a living or deceased animal, with a known 
concentration of any drug.   
 Samples with known drug concentrations for the standard curves were treated with 3 mL 
of 1:1 MeOH:ACN for lipid-protein precipitation for 12 hours at -20°C.  Sample supernatant was 
isolated from the precipitated solids into clean test tubes following centrifugation at 4000 rpm 
(1500 x g) for 10 minutes using a Clinical 100 micro-centrifuge from VWR Analytical and then 
evaporated to a volume of 1 mL using the CentriVap® concentrator and cold trap. 
 Samples were prepared for mixed-mode solid phase extraction (SPE) to isolate drugs and 
internal standards from unwanted compounds present in the supernatant.  100 μL of GAA was 
added to each test tube to increase extraction efficiency by protonating the drugs and internal 
standards for anion interactions during extraction.  All samples were diluted with 1.5 mL of PBS 
prior to loading on the SPE well plate.  Clean Screen® XCEL I 96 well plates from United 
Chemical Technologies were used for SPE.  The Xcel 1sorbent material is a mixed-mode anion 
material, allowing neutral and positive charged molecules to adsorb to the surfaces of the sorbent.  
Each well was conditioned for SPE with sequential 1.5 mL volumes of MeOH to wet the SPE 
resin, distilled water to wash out any residual MeOH, and PBS to promote sample-sorbent 
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interaction by giving the well environment a pH of 6.0, well below the pKa values for DXM and 
DXT (8.3 and 9.2, respectively).  Samples were loaded by gravity following well conditioning.  
Wells were sequentially washed with 1.5 mL volumes of PBS, 0.1M acetic acid and MeOH, with 
a 5 minute drying time using a Rocker 400 vacuum pump from Rocker Scientific (Linkou District, 
Taiwan) at -50 kPa prior to the latter wash, and again for 10 minutes following the final MeOH 
wash.  Drugs were eluted from the columns with a 3:17:80 solution of NH4OH:ISO:EA and 
collected in a dry 96 well elution plate from United Chemical Technologies, which was cleaned 
prior to each drug elution by 5 minute sonication bath using a FS20D Digital Ultrasonic Cleaner 
from Fisher Scientific.  Eluted drugs were pipetted into clean test tubes using Pasteur pipettes and 
then evaporated to dryness under vacuum using a CentriVap® Concentrator.  Dried samples were 
reconstituted in 50 μL of EA and received 50 μL of the derivatizing agent MSTFA+1%TCMS 
using Positive Displacement Microdispensers from Drummond Scientific Company (Broomall, 
PA).  Tubes were capped and vortexed for 30 seconds and the samples were derivatized at 70°C 
on an Analog Heatblock from VWR Analytical for 60 minutes.  Derivatized samples were 
transferred to 200 μL glass MicroSert Inserts from ThermoScientific (Rockwood, TN) in 1.8 mL 
amber glass autosampler vials from VWR International for GC/MS analysis. 
2.6 Experimental Sample Preparation 
 Each rat was dissected individually with control animals harvested first to prevent 
downstream contamination.  Bone elements from each animal where cleaned, washed and 
pulverized individually using the methods presented above.  Pulverized bones were stored in clean 
glass test tubes prior to drug extraction and analysis.  Of the bones collected from each animal, the 
skeletal elements that were prepared for analysis were skull, vertebrae, humerus, scapula, pelvic 
girdle, femur and tibia.  Drugs were extracted by MAE using 0.2 g of pulverized bone from each 
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element in individual reaction vessels.  Blood volumes of 0.25 mL were diluted to 1 mL volumes 
with PBS and treated with the same methods as bone samples following MAE for SPE and 
derivatization. 
2.7 GC/MS Analysis 
 Analyses were performed on a Clarus 600C Gas Chromatography-Mass Spectrometry 
instrument in Selected Ion Monitoring (SIM) and Full Scan (FS) modes with TurboMass 
v.5.4.2.1617 software from PerkinElmer LAS (Shelton, CT) using a Zebron ZB-Drug-1 column 
(Phenomenex, Torrance, CA).  Extracts of 2 μL from derivatized samples were injected into the 
instrument’s injection port held at 250 °C.  Initial oven temperature was held at 100 °C for 3 
minutes before ramping for 15 minutes to 220°C at 10°C per minute.  Oven ramp rate decreased 
to 5°C/min for 6 minutes to 250°C to aid in resolution of targeted parent and metabolite peaks 
from endogenous compounds.  Oven temperature ramped at 10°C /min until 300°C was reached 
and held for 3 minutes to finish the run.  The total run time of each analysis was 31 minutes.  A 
retention time standard of 1000 ng of derivatized pure drugs was run at the beginning of each series 
of analyses to identify the elution times of the targeted compounds.  DXM was quantified by m/z 
ion 271, DXT with ion 150 and dmDXT with ion 315, d3-DXM and d3-DXT were quantified with 
m/z ions 274 and 153 respectively from peak area integrations calculated by TurboMass software. 
2.8 Method Validation 
 Proficiency and method repeatability was demonstrated by completing 3 standard curves 
on different days per Scientific Working Group for Forensic Toxicology (SWGTOX) 
recommendations (70) using the methods presented by Fraser, et al (9).  Triplicate samples of 9 
concentrations ranging from 0 to 2000 ng of drugs in 1 mL of drug free bone extract were used to 
produce the standard curves.  DXT was quantified with the ion m/z ratio of 329 and ions 272 and 
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150 were used to qualify DXT.  Initial standard curves were validated with these ions.  Internal 
standard d3-DXT was quantified with ion 332 and qualified using ions 275 and 153.  DXM was 
quantified with 271 ion and qualified with 214 and 150 ions, d3-DXM was similarly identified by 
ions 274, 217 and 153.  The secondary metabolite dmDXT was quantified using ion 315 and 
qualified by 270 and 136 m/z ions.  Retention times for DXM, DXT, dmDXT and corresponding 
internal standards were 18.95, 19.27 and 19.54 minutes, respectively.  Drugs and internal standards 
were identified by their retention times and mass spectra.     
 During experimental analyses, an endogenous compound with a strong 329 ion response 
was present in a number of samples and could not be fully resolved from DXT 329 ion peaks.  This 
interferent was present in samples from both sites but was predominant in Site B analyses.  The 
DXT interferent was absent in all samples during validation.  Sample and standard curve results 
were reassessed for DXT quantifying and qualifying ions not present in the interferent.  To 
distinguish DXT from the interferent, with m/z ion 150 was used to quantify and those with m/z 
59 and 214 were used as qualifying ions.  Figure 2.1 presents an example chromatogram with 329 
ion interferent and reassessed 150 ion response.  The internal standard was similarly reassessed 
and ions 153, 62 and 217 were used to identify d3-DXT.  All standard curves and experimental 
results that follow for DXT and d3-DXT were calculated using 150 and 153 as quantifying ions, 
respectively.   
Quantification of drugs was calculated using Response Ratios (RR) where drug quantifying 
peak areas were divided by quantifying internal standard peak areas; d3-DXM served as the 
internal standard for dmDXT.  Method validation calculations were completed using Excel® 2013 
(Microsoft Corporation, Redmond, WA).  The response ratio (RR) formula is presented below: 
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𝑅𝑅 =
𝐷𝑟𝑢𝑔 𝑄𝑢𝑎𝑛𝑡𝑖𝑓𝑦𝑖𝑛𝑔 𝐼𝑜𝑛 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑄𝑢𝑎𝑛𝑡𝑖𝑓𝑦𝑖𝑛𝑔 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
 
Each set of replicate standard curves were assessed by the coefficient of determination (R2) and 
the coefficient of variance (CV%) for DXM, DXT and dmDXT results.  Bias was assessed by the 
inclusion of two samples of unknown concentrations prepared in triplicate for comparison of fit to 
the linear model from the standard curve results.  Variance in DXM and DXT results were within 
CV% limits 20% down to a limit of quantification (LOQ) 10 ng/mL samples, however the LOQ is 
more reliably 25 ng/mL, the LOQ used in this study.  Results for DXM and DXT linear models 
showed good fit with R2 values ranging from 0.9916-0.9991 and from 0.9893-0.9996 respectively.  
Bias results for DXT and DXM were all satisfactory with no value falling outside ±20% of the 
linear models.  The results of dmDXT analyses were not sufficient for validation.  Limit of 
detection of dmDXT from standards curves was 500 ng/mL and CV% were in excess of accepted 
limits across all detected concentrations.  Though dmDXT can be detected, dmDXT cannot be 
used for quantification in this study given the poor recovery and the dispersion of standard curve 
results.  Standard curves and validation calculations are presented in the Appendix. 
2.9 Experimental Sample Analyses 
 Drug and metabolite chromatogram peaks were identified from GC/MS analyses using 
mass spectra of DXM, DXT and dmDXT and comparison to retention time standards.  Drug and 
internal standard responses were calculated from TurboMass peak area integrations for RR values 
calculated in Excel spreadsheets.  All experimental samples were normalized for mass (RR/m) to 
account for variability in the masses of milled bone tissues used in sample preparation by dividing 
relative responses by sample mass:   
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𝑅𝑅
𝑚⁄ =
𝐷𝑟𝑢𝑔 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑅𝑎𝑡𝑖𝑜
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑖𝑠𝑠𝑢𝑒
 
 Blood volume was used to normalize results of blood analyses.  Whole blood density is 
approximately 1.05 g/mL, so blood volume and blood mass are essentially equivalent for purposes 
of this study (71).   
 Statistical analysis of results was completed using Excel® 2013 and StatPlus:Mac 2009 v 
5.8.3.8 (AnalystSoft Inc., Wallnut, CA).  Blood correlations across bone types was calculated by 
the square of Pearson product moment correlation coefficient (R2).  Kolmorov-Smirnov tests 
determined non-normal distribution of data so nonparametric analyses were used in this study.  
Drug and metabolite responses were compared across bone elements and decomposition sites by 
Mann-Witney U tests with significant differences acknowledged for p values less than 0.05 (p < 
0.05).  Kruskal-Wallis tests compared distributions across bone types with statistical significance 
at p < 0.05.  Analytical results are presented in the Appendix. 
2.10 Microclimate Measurements and Data Analyses 
 Environmental measurements were collected throughout the experiment to establish 
microclimate differences at Sites A and B.  Six HOBO® H08-32-IS data loggers and additional 
environmental instruments were provided for this study by Dr. Jaqueline Litzgus and Dr. Gerard 
Courtin of the Biology Department at Laurentian University to establish different microclimatic 
conditions at Sites A and B.  Data logger temperature measurements were verified using an Omega 
HH-25TC Type 1 Thermocouple (Omega Engineering, Inc., Stamford, CT).  Relative humidity 
measurements were verified against a Kestrel® 3000 Pocket Weather Meter (Nielsen-Kellerman, 
Chester, PA) and against equilibrium relative humidity of different saturated salt solutions and 
pure water in a sealed vessel (72).  Data loggers sat above saturated solutions for 1 hour recording 
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measurements every 5 minutes to test humidity sensors against known RH values of 33%, 53% 
and 75% for saturated salt solutions of magnesium chloride, magnesium nitrate and sodium 
chloride salt, respectively (72).  Pure water was used to test for 100% relative humidity.  Data 
logger measurements for temperature and RH% were also compared against a Taylor Precision 
Products (Oakbrook, IL) 1328 Sling Psychrometer at Sites A and B, and in the Laurentian 
University forensic toxicology laboratory.   
 Temperature measurements from all 6 data loggers showed good fit with all other 
instruments used in verification.  Relative humidity testing showed only three data loggers had 
functioning RH sensors.  Data loggers with working RH sensors showed good fit with the Kestrel 
and sling psychrometer measurements and were within expected instrument error margins of ±2% 
RH and sensor drift over time for all saturated salt solutions and pure water sealed container tests.  
Plots of RH% validation are presented in the Appendix. 
Ambient microclimate measurements were collected using the three HOBO® data loggers 
with working RH sensors.  Two sensors were mounted 3 cm (lower) above decomposing rats at 
Sites A and B and the third 1.5 m (upper) above ground at Site A per convention.  Temperature 
and RH% measurements were recorded hourly from July 7th to July 30th, 2016.  Absolute Humidity 
(AH), the mass of water vapor in a parcel of air (g/m3) was recorded by BoxCar® Pro v. 4.3.1.1 
software (Onset Computer Corporation) from each hourly temperature and RH% measurements 
when data was downloaded from the HOBO® dataloggers.  Recorded AH values were verified 
from calculations using measured temperatures in degrees Celsius (T) and relative humidity 
(RH%) with the formula: 
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝐻𝑢𝑚𝑖𝑑𝑖𝑡𝑦 (𝑔𝑟𝑎𝑚𝑠 𝑚3⁄ ) =  
6.11 × 10(7.5 ×𝑇) (𝑇+273.3)⁄  × 𝑅𝐻% ×  2.1674
273.15 + 𝑇
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The formula is based on the Ideal Gas Law and Tetens saturated vapor pressure equation, the latter 
used to calculate accurate water vapor pressures over the temperature ranges observed during the 
study (73, 74).  AH was calculated to assess atmospheric moisture content between microclimate 
sites.  Downloaded AH values at each site were compared against calculated AH values by Mann-
Whitney U tests to check data logger accuracy.  Microclimate measurements were downloaded 
after the first day of the experiment to ensure data logger function, again after 7 days and finally 
at the end of the experiment.  Differences in microclimate parameters between sites was assessed 
by Mann-Whitney U tests.  Hourly regional weather data was obtained from Weather Canada (75) 
at the Greater Sudbury Airport, approximately 22 km from the decomposition sites at Laurentian 
University if regional comparison with microclimate measurements was warranted. 
  
 
 
29 
 
CHAPTER 3 
RESULTS 
3.1 Microclimate Analysis 
Boxplot distributions of microclimate data are presented in Figure 3.1.  Site B (exposed) 
microclimate data exhibited warmer and drier RH% conditions.  Greater variability in Site B 
microclimatic parameters is evidenced by wider interquartile ranges (IQR) for temperature and 
RH% measurements relative with those at Site A (forested).  Site A distributions for AH showed 
higher minimum and maximum AH values than at Site B though means and IQRs for Sites A and 
B appear similar.  Average, maximum and minimum recorded values for temperature, RH% and 
AH (g/m3) are presented in Table 3.1.  Mann-Whitney U tests were used to assess differences in 
Sites A and B microclimates.  Significant differences were noted for temperature (p = 0.006) and 
RH% (p = 0.006) between Site A and Site B microclimates.  Because AH, the amount of water 
vapor in air (g/m3) above the animals were not significantly different (p = 0.27), differences in 
decomposition rates were attributed to sunlight and temperature.  Downloaded and calculated AH 
values at Site A and Site B show no significant differences (Site A p = 0.97, Site B p = 0.96).   
Animals at Site A were in a shaded forest area with prolonged insect activity that yielded 
skeletonized remains.  Insect activity during the first few days of decomposition at Site B was 
much higher than at Site A.  The initial presence of more insects at Site B is attributed to the rapid 
onset of bloat, but insect activity at Site B dropped off sharply as the study progressed.  Conditions 
at the Site B led to mummified and partially skeletonized remains with much of the muscle tissues 
and internal organs preserved in Site B animals.  Intestinal chyme was present in the remains of 
some of the Site B animals, indicating both insect and digestive microbial activity was supressed 
under the conditions at the exposed microclimate.   
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Figure 2.1: Distributions of microclimate parameters at Site A (forested) and Site B (exposed).  
Relative humidity (RH%) and temperature (°C) were significantly different between sites while 
absolute humidity (g/m3) had no significant differences. 
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Table 3.1: Summary of microclimate parameters temperature (°C), relative humidity (RH%) and 
absolute humidity (g/m3) during differential decomposition.  Statistical significance (p < 0.05) 
between Sites A and B for microclimate parameters reflect significant differences in temperatures. 
Microclimate Variable Site A Average (Range) Site B Average (Range) p-Value 
Temperature (°C) 20.8  (8.9-38.8) 22.0  (9.0-39.1) 0.006 
Relative Humidity (%) 68.6  (16.6-100.0) 64.4  (15.8-99.9) 0.006 
Absolute Humidity (g/m3) 11.9  (6.5-19.7) 11.7  (6.1-18.4) 0.27 
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3.2 Expression of Drug Levels 
 Mass normalized response ratios (RR/m) for DXM and DXT measurements are presented 
in this study as in previously published works (12, 14, 18, 31).  Proper calibration of analyte 
recovery from a heterogeneous sample matrix like bone tissue cannot be assessed using 
conventional techniques as the bone matrix cannot be homogenized with internal drug standards.  
DXT m/z ion 150 and interferent m/z ion 329 comparisons are summarized in Figure 3.1.   
Normalizing measured response ratios with the mass of the sample allows the comparison of 
different drug responses prepared using the same methods as RR/m is proportional to the 
concentration of drug in bone.  These values should be viewed as approximations of bone-drug 
concentrations only as accurate calibration of an analyte from solid matrices is not possible.  
Estimated concentrations of DXM and DXT are presented below in Table 3.2. 
3.3 Influence of Bone Elements on Drug Distribution 
 DXM and DXT were detected in all analyzed drug-positive skeletal elements from both 
microclimate sites, but some DXT (n = 9) responses were below the LOQ and were excluded from 
quantitative comparison.  Mean DXM RR/m responses across bone elements were larger than all 
corresponding mean DXT values.  Mean drug levels in bone elements from Sites A and B for 
DXM, DXT and metabolite-parent mass normalized ratios (RRDXT/RRDXM) are presented in Figure 
3.3.  Differences in drug responses across bone elements within animals at each microclimate site 
were assessed using Kruskal-Wallis tests to test bone element as an effect on drug distribution.  
No significant statistical differences (p > 0.05) for DXM or DXT were seen across bone elements 
at Site A or Site B.  Kruskal-Wallis analysis of the RRDXT/RRDXM ratios at Site A were 
insignificant.  Site B ratios showed statistically significant differences across bone elements (p = 
0.048) but lacked significant bivariate differences by Dunn’s multiple comparison post hoc tests. 
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Figure 3.2 Example DXT reassessment of ACU B-2 and B-3 vertebrae samples with ion 150 due 
to ion 329 endogenous interferent.  The predominant 329 interferent elutes 0.09 minutes after DXT 
and prevents resolution of the metabolite from endogenous compounds using ion 329.  DXT was 
assessed and revalidated using ion 150 (ion 153 for d3-DXT) for all experimental analyses and 
standard curves used in this work. 
  
DXT 150 (19.04 minutes) 
DXT 329 interferent 
(19.13 minutes) 
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Table 3.2: Estimated DXM and DXT concentrations in bone samples between Sites A and B.  
Estimated drug concentrations were calculated from standard curve plots and drug responses, and 
corrected for sample bone mass.  These concentrations should be viewed with caution and at best, 
estimates only, as concentrations from solid matrices cannot be validated using standard 
toxicological methods. 
 Site A DXM (ng/g): Site B DXM (ng/g): Site A DXT (ng/g): Site B DXT (ng/g): 
Maximum Drug 
Concentration 
10,474 8,726 3,045 3,668 
Minimum Drug 
Concentration 
399 3,435 142 133 
Range 10,075 5,291 2,903 3,535 
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Figure 3.3: Average mass normalized response ratios (RR/m) for DXM and DXT, and ratio of 
mass normalized response ratios of DXT to DXM (RRDXT/RRDXM) from decomposed bone 
elements for Site A (forest) and Site B (exposed) microclimates following acute i.p. (75mg/kg) 
DXM administration. 
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3.4 Influence of Microclimate on Drug Distribution 
Microclimate differences were established in this study and drug responses were tested 
across the different decomposition environments.  Box plot distributions of observed drug levels 
(RR/m) for DXM, DXT and metabolite-parent ratios (RRDXT/RRDXM) for Sites A and B are 
presented in Figure 3.3.  Site A DXM and DXT levels expressed greater variations in response as 
larger IQRs vs. Site B DXM and DXT distributions.  Site B metabolite/parent ratios skew towards 
higher values with greater variation than at Site A.  Differences in pooled observations for DXM 
and DXT levels, and RRDXT/RRDXM values between microclimate sites were assessed using Mann-
Whitney U tests.  No statistically significant differences were seen in pooled drug responses or 
metabolite-parent ratios between microclimate sites.  Differences for DXM, DXT and 
RRDXT/RRDXM levels in each skeletal element between microclimate sites were evaluated by 
Mann-Whitney U tests.  Only one significant difference in RR/m (femoral DXM, p = 0.0472) was 
observed between microclimates.  DXT responses and metabolite/parent ratios show no significant 
differences within bone elements between Site A and Site B.   
Examination of RR/m shows a higher variability for DXM and DXT levels (expressed as 
the ratio of maximum to minimum drug levels) at the forested microclimate, Site A.  Table 3.2 
summarizes the variability in observed drug responses and metabolite-parent ratios for Sites A and 
B across different bone elements, within animals and for pooled data.  DXM and DXT show 22-
fold and 52-fold variations, respectively, at Site A, and 10-fold and 18-fold variations for DXM 
and DXT, respectively, at Site B.  The maximum variations for DXM and DXT are both within 
given bone elements (Table 3.2), indicating skeletal element may be a factor, though below 
statistical significance, in DXM and DXT distribution.  Calculated R2 values, means, coefficient 
of variance (CV%) and standard deviations of RR/m values are presented in Table 3.3.    
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Figure 3.4: Distribution of pooled mass normalized response ratios (RR/m) for DXM and DXT, 
and ratio of mass normalized response ratios of DXT-to-DXM (RRDXT/RRDXM) for all bone 
elements from Site A (forest) and Site B (exposed). No significant differences across sites were 
observed. 
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Table 3.3: Mean, standard deviation (SD), coefficients of variance (CV%), and Pearson correlation 
with blood (R2) of RR/m and metabolite-parent ratios for all analyzed skeletal elements. 
Site A: Vertebrae Femur Ribs Tibia Pelvis Skull Scapula 
DXM               
Mean: 22.62 12.52 23.68 23.91 16.38 18.11 29.81 
SD: 10.04 2.85 12.43 6.55 9.71 11.80 15.39 
CV%: 44.4 22.8 52.5 27.4 59.3 65.2 51.6 
R2: 0.03 0.01 0.21 0.17 0.10 0.00 0.12 
          
DXT         
Mean: 5.07 1.59 4.36 2.30 3.50 6.85 5.54 
SD: 3.69 0.34 3.47 0.81 2.79 5.55 3.33 
CV%: 72.8 21.6 79.5 35.2 79.7 81.0 60.1 
R2: 0.06 0.10 0.15 0.84 0.04 0.34 0.97 
          
RRDXT/RRDXM         
Mean: 0.20 0.14 0.17 0.10 0.19 0.29 0.20 
SD: 0.09 0.05 0.09 0.04 0.07 0.16 0.05 
CV%: 43.5 36.8 52.3 35.3 38.7 52.9 26.9 
R2: 0.15 0.34 0.02 0.60 0.01 0.29 0.22 
        
        
Site B: Vertebrae Femur Ribs Tibia Pelvis Skull Scapula 
DXM               
Mean: 15.04 25.00 22.60 21.00 15.90 19.09 15.41 
SD: 3.32 10.04 11.98 7.82 12.91 7.21 10.75 
CV%: 22.1 40.2 53.0 37.3 81.2 37.8 69.7 
R2: 0.30 0.00 0.01 0.89 0.17 0.27 0.08 
          
DXT         
Mean: 4.28 4.16 7.19 2.04 5.67 5.36 6.77 
SD: 0.63 3.57 5.04 0.68 2.46 3.64 3.95 
CV%: 14.7 85.9 70.0 33.5 43.4 68.0 58.3 
R2: 0.47 0.01 0.15 0.02 0.57 0.49 0.03 
          
RRDXT/RRDXM         
Mean: 0.28 0.15 0.29 0.10 0.60 0.29 0.52 
SD: 0.05 0.07 0.09 0.03 0.40 0.13 0.39 
CV%: 17.3 48.0 31.1 32.1 67.3 44.9 74.9 
R2: 0.20 0.08 0.11 0.06 0.90 0.08 0.85 
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Variability in drug responses was examined across different bone elements, within animals 
and pooled results expressed as the ratio of maximum to minimum RR/m values for DXM, DXT 
and RRDXT/RRDXM.  Table 3.4 presents calculated max/min measures of variability.  Variability is 
highest across different bone elements at both microclimate sites, showing that different bones, as 
seen in previous studies may be factor in drug distribution (12, 14, 18, 31).  Differences in 
variability across microclimates is shown, indicating potential microclimate influence on 
recoveries of DXM and DXT.  Variability is highest at Site A with factors of 22 and 52 for DXM 
levels and DXT levels, respectively, versus 10 fold for DXM levels and 18 fold for DXT levels at 
Site B.   
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Table 3.4: Ratio of maximum to minimum (Max/Min) response for DXM and DXT, and 
metabolite-to-parent ratios (RRDXT/RRDXM) at Site A (forest) and Site B (exposed) microclimates 
Analyte 
Observed Max/Min Range 
Within Bone Elements 
Observed Max/Min Range 
Within Animals 
Max/Min Pooled Bone 
and All Animals 
DXM     
Site A 2.1-22.3 2.7-8.5 22 
Site B 1.6-7.9 2.1-5.1 10 
      
DXT     
Site A 2.0-51.5 5.2-14.4 52 
Site B 1.4-13.2 3.9-7.6 18 
      
RRDXT/RRDXM     
Site A 2.2-12.4 2.1-6.3 19 
Site B 1.7-11.6 3.5-15.7 19 
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CHAPTER 4 
DISCUSSION 
4.1 Study Overview 
To our knowledge, this is the first study to compare drug responses from bone tissues in 
skeletonized remains having established microclimatic differences across decomposition sites 
wherein environmental conditions were measured above the surface of decomposing, drug-
positive animals.  The rates of decomposition have been shown to be controlled by environmental 
conditions, largely temperature and moisture content, by dictating the biological and biochemical 
processes during decay such that the degree and speed of decomposition will differ across 
microclimates and weather events (19, 65, 67).  Observed drug levels in bone tissues have been 
shown to vary across different decomposition environments (17, 18).  The microclimate factors 
controlling decomposition may also influence the distribution of drugs in bone tissues directly or 
by limits placed on decomposition processes.  Drugs have been found in soil substrates below 
decomposed remains, in maggots feeding on drug-positive remains and in the bone tissues at the 
base of positioned remains (18, 24, 76–78).  If the degree of insect activity and liquefaction of a 
decomposing body influences the degree of drug partitioning into bone from decomposing soft 
tissues, these processes will be dictated by microclimate conditions.   
 The objectives of this study were to establish environmental differences and assess 
microclimate and bone element effects on the recovery of DXT and its metabolites from 
decomposed bone tissues.  Because dmDXT standard curve responses could not be validated, 
quantified results were limited to DXM and its primary metabolite DXT.  The results from this 
study show limited agreement with previous studies from our laboratory.  Bone elements and 
microclimate have shown to be a major influence on distributions of drugs in bone tissues (12, 14, 
18, 31).  Microclimate and bone elements showed no significant influence on observed DXM or 
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DXT values, indicating bone as a drug reservoir may behave uniformly for certain drugs across 
different environments of decomposition. 
4.2 Differential Decomposition 
 The physical condition of rat remains between Sites A and B exhibited distinct patterns of 
decomposition.  Rats at Site B mummified with muscular soft tissues dried and well preserved 
while Site A animal remains had flattened and partially skeletonized by the end of 3 weeks of 
outdoor exposure.  Typical appearances of rat remains at the conclusion of decomposition are 
presented below in Figure 4.1.  Temperatures during decomposition is shown to be a major 
influence on decomposition, with observed differences in the conditions of remains and significant 
temperature differences across Sites A and B.  RH% value were also significantly different 
between the sites, but since relative humidity is a function of temperature as well as water content 
in the air, the differences in RH% between Sites A and B reflect the differences in temperature.  
Microclimates during day (sunrise to sunset) and night (sunset to sunrise) were compared between 
sites by Mann-Whitney U tests.  Microclimates during the night had no significant differences for 
recorded measurements.  Temperature and RH% during the day were significantly different 
between sites with p = 0.00002 and p = 0.0001 for temperature and RH%, respectively.  Because 
the differences were present during daylight hours, variation in microclimates can be attributed to 
differences in sun exposure.  Figure 4.2 presents the distributions of day and night microclimate 
parameters at Sites A and B.  AH, the amount of water vapor in air (g/m3) measured 3 cm above 
decomposing remains was not significantly different between sites or between day and night site 
comparisons.  As the atmospheric water content above decomposing remains is similar at both Site 
A and Site B, variation in decomposition is attributed to temperature differences due to different 
sun exposure.    
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Site A Rat ACU-4  
Site B Rat ACU-5  
Digestive organs with 
preserved chyme 
Preserved intercostal 
muscle and heart 
tissues 
Flattened, partially 
skeletonized remains 
lacking internal organs  
 
Figure 3.1: Differential conditions of rat remains following decomposition at Site A (forested) and 
Site B (exposed).  Rats at Site A were partially skeletonized and lacked internal organs while Site 
B rats retained much of their muscle and internal organ tissues.  The presence of undigested chyme 
in Site B rats indicates microbial action by digestive bacteria was supressed early on at Site B. 
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Figure 4.2: Distribution of microclimate parameters during day and night hours.  Significant 
differences were observed between Sites A and B during daylight hours for temperature (p = 
0.00002) and relative humidity (p = 0.0001) by MW U test analysis.  No significant differences 
between sites are observed for night (sundown to sunup hours) microclimate measurements. 
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Differences in insect activity were also noted between microclimate sites.  Loss of drugs 
from soft tissues due to insect activity (76–78) may impact post-mortem redistribution of drugs 
from liquefied remains on to the surfaces of, or in to, bones.  Initial insect activity was higher at 
Site B than at Site A, the increase in insect activity may be due to rapid bloat and release of early 
decomposition products that was brought on by higher temperatures and sun exposure.  Insect 
activity at Site B dropped off sharply as the study progressed and remained lesser than the insect 
action at Site A, especially for maggot presence and activity.  The degree of insect activity will be 
influenced by the temperature and humidity of the environment.  An experiment found hour long 
exposures to RH% and temperatures encountered during this study at Site B lethal to a number of 
arthropod species (79).  If insects are indeed a factor in drug in bone responses, exclusion of insects 
by environmental conditions will limit any effect insects have on drug levels. 
4.3 Comparing Bone and Blood Drug Responses 
 Some work has been done to establish corollary relationships with bone and blood drug 
concentrations.  To test for this, blood was taken from each animal perimortem from all animals 
except ACU-A4, which perished prior to blood sampling.  Correlations between blood and bone 
element RR/m values from each animal for DXM and DXT were assessed using Pearson 
correlation coefficients (R2).  Calculated R2 values, means, coefficient of variance (CV%) and 
standard deviations of RR/m values are presented above in Table 3.3.  Blood samples of 0.25 mL 
from each animal were spiked with 200 ng d3-DXM and d3-DXT internal standards and were 
prepared and extracted using the same methods for bone tissue extractions.  As the density of blood 
is approximately 1.05 g/mL, volume was used to calculate mass normalized response ratios in 
blood (71).  Only one (1/42) correlation of note, Site A DXT scapulae (R2 = 0.973), was observed 
for all calculated blood to bone Pearson coefficient correlations.  
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Of all calculated R2 values, 41/42 showed no significant correlation between blood and 
bone drug responses.  The observed bone to blood correlations in this study reflect previous work 
(18, 31).  The Site A DXT scapula correlation that appears significant may be due to insignificant 
sample size to achieve statistic validity given the lack of blood from Animal ACU-A4, or perhaps 
under these experimental conditions, DXT responses in Site A scapula elements approach an actual 
correlation.  The processes that dictate drug sequestration in bone tissues are varied and complex 
and will be influenced by drug properties, post-mortem environment, variations in individual 
metabolic rates and other factors yet to be accounted for in drugs in bone studies (3, 4, 8, 10, 12, 
14, 16, 17, 28, 29, 80, 81).  Because all the factors that influence drug in bone levels have yet to 
be sufficiently addressed, any correlations made between blood and bone drug responses should 
be viewed with caution.  
4.4 Drug in Bone Responses 
Only one comparison, femoral DXM levels, displayed significant differences between 
microclimate sites (p = 0.047).  Within bone element comparisons did not exhibit significant 
differences between microclimates for remaining DXM values, all DXT responses and all 
metabolite to drug ratios.  Marked differences in microclimates and insect activities did not impact 
levels of DXM or DXT from bones recovered after differential decomposition.  Drug distribution 
did not differ significantly between bone elements, contrary to what has been observed in previous 
work from our laboratory (12, 14, 18, 31).  Observed drug distributions may reflect post-mortem 
properties of DXM and DXT, the metabolic rates of the species or individual rats used in this study 
(48, 80, 81), as well as the specific microclimate conditions encountered.   
 Estimated bone-drug concentrations were calculated from responses above LOQ values and 
standard curve plots, and then normalized for bone tissue sample masses.  Estimated sample 
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concentrations are presented below in Table 4.1.  Estimated concentrations of drugs in bone at Site 
A ranged from 399 to 10,474 ng/g for DXM and 142 to 3,045 ng/g for DXT.  Site B concentrations 
ranged from 3,435 to 8,727 ng/g DXM and 133 to 3,668 ng/g DXT.  These calculated 
concentrations are at best estimates given that solid matrices like bone tissues prevent conventional 
calibration or recovery measurements.  All 70 experimental DXM values from both sites were 
above the LOQ values (25 ng) established during method validation.  All DXT responses from 
Site B were above LOQ values (25 ng), while 29/35 Site A DXT values were above the LOQ.  
Though no statistically significant differences for any drug responses between sites were observed, 
the differences in absolute ranges of drug responses between sites A and B, in addition to the 6/35 
Site A DXT values below LOQ may speak to some microclimate influences on drug distributions.   
Although in previous studies (17, 18) the environment during decomposition has been 
shown to effect drug distributions in bone tissues, the lack of significant differences across 
microclimates observed here may be a function of DXM and DXT properties or insufficient 
numbers of samples used in this study.  Patterns of drug-metabolite ratios observed in experiments 
in acute vs. repeated doses have been useful in discriminating between different drug dosing 
patterns (7, 82), and have been seen in decomposed bone tissues (12, 14, 18).  Metabolite/parent 
ratios may offset variations in drug and metabolite measurements in different bones.  The 
RRDXT/RRDXM values presented here can go to future work comparing drug-metabolite ratios 
between different dosing patterns and assessing the role of parent-metabolite ratios in accounting 
for the wide variations seen in toxicological analyses of drugs from different bone elements.     
 The results of this study show limited agreement with previous work on drug recoveries 
from decomposed bone tissues.  The effect of environment on drug recoveries from bone has been 
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shown to have significant impact (17, 18), variations in this study across microclimates are not 
significant, however this may reflect insufficient sample size used in this study.   
The degree of liquefaction of soft tissue remains may be a factor in the distribution of DXM 
or DXT in bone tissues.  Drug presence in bone is hypothesized to reflect high marrow and 
trabecular bone contents as these offer the highest surface areas for drug into bone partitioning.  
Certain pharmaceuticals, like tetracycline have been shown to have “bone seeking” properties and 
can be sequestered in bone while low systemic concentrations are observed. (29).  The affinity a 
given drug has for bone will affect the degree of distribution into bone tissues and potentially drug 
stability during decomposition and should be considered when interpreting drug responses in bone 
tissues.  Different bone elements appear to be a factor in the distribution of DXM and DXT, though 
not to the significance seen in previous studies (12, 14, 16, 18, 31).  The distribution and variation 
of drug levels in this study show that at best qualitative interpretations may be made from 
toxicological analyses of bone at this stage, until the viability of quantitative relationships between 
drug and metabolite levels may be more systematically investigated. 
4.5 Validation Problems of 3-hydroxymorphinan 
 The recovery of 3-hydroxymorphinan (dmDXT) using the methods of this study was 
insufficient to meet validation requirements.  Pure dmDXT standard in methanolic solutions for 
use in retention time standards showed substandard peak areas and lacked uniformity while DXM 
and DXT performed as expected, following previously published studies (9).  Glass-drug 
interaction was suspected given that pure dmDXT drug standard was not appearing adequately in 
retention time standards.  Retention time standard preparation methods were changed to address 
dmDXT recovery and 1 mL of drug-free, control bone tissue broth was evaporated to dryness to 
“line” the inside of the retention time test tube before the addition of drug standards and 
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derivatization.  This was tried to test if dmDXT was interacting with and adhering to the glass 
walls of the test tubes used in the study.  Retention time standard analysis benefited from the 
updated method and dmDXT peak widths and areas somewhat improved.  
 Recovery of dmDXT was poor in standard curve analyses and the validation of dmDXT 
was abandoned.  However, dmDXT could still be identified by its retention time and mass spectra 
in experimental samples, though dmDXT peaks were often broad, irregular and sometimes 
unresolved.  At the conclusion of this study, test tubes were silylated to further test for dmDXT-
glass interactions.  Retention time standards from pure drug standards (DXM, DXT and dmDXT) 
in standard and silylated tubes were prepared and analyzed by the GC/MS methods used in this 
study.  No improvement in dmDXT peak shape and area were seen using silylated tubes.  The 
results here may indicate that glass wall interactions with dmDXT may not the cause of poor 
dmDXT analyses.  Testing different derivatizing agents may address the poor dmDXT results seen 
in this study.  Given that DXT derivatization of the 3-hydroxy group (shared with dmDXT) gives 
reproducible results, the derivatization of the secondary amine group on dmDXT using the 
methods of this study may not be sufficient to provide required volatility for GC methods.  For 
future GC studies, analysis of dmDXT may benefit from testing different derivatization agents. 
4.6 Future Work 
 Without a large database of different drug responses and established standard methods, 
interpretation of quantitative measurements of drugs from bone tissues is not possible.  The 
interpretation of drug responses in decomposed bone is difficult.  Given the heterogeneity in bone 
morphology and physiology, genetic polymorphisms in metabolism, changes in stability and bone 
seeking properties across drugs, differences in biological and biochemical decomposition 
processes and the microclimate conditions present during decomposition, a number of factors 
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should be considered when interpreting drug responses in bone tissues (19, 27, 29, 67, 80, 81).  
Substantial variation in drug and metabolite responses may be corrected for by parent-metabolite 
ratios in some cases (12, 14, 82).  It is important to include consideration of as many major 
metabolites as possible in such investigations.  Here, the investigation was limited to the parent 
drug and only one metabolite, but the results can go to comparing administration patterns of DXM 
with its major metabolite DXT.  Similar studies should be undertaken using larger sample sets to 
establish statistically sound patterns and trends across different microclimates to allow for the 
interpretation of drug responses from bone tissue analysis.  
 The use of new analytical methods should also be explored.  Given the issues with dmDXT 
in this study, liquid chromatography methods with suitable detection instruments may benefit the 
analysis of DXM and its metabolites from biological samples by reducing sample preparation and 
eliminating derivatization steps.  Recent advancements in analytical chemistry may make 
quantifying and identifying drugs, metabolites and endogenous compounds from a variety of 
biological or environmental sample matrices possible in single sample analyses from the atomic 
masses and mass spectra of analytes using Quadrupole Time-of-Flight (Q-Tof) UPLC/MS methods 
(83–88).  Q-Tof methods may help to establish larger drug and metabolite databases that can aid 
the interpretation of metabolite-drug ratios from post-mortem tissue samples with regards to drug 
exposure patterns and potential microclimate effects.  
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CHAPTER 5  
CONCLUSION 
To our knowledge, this is the first study to establish closely measured microclimate 
parameter differences during decomposition for comparison of drug and metabolite distributions 
in bone tissues.  The degree of soft tissue liquefaction may play a role in post-mortem redistribution 
of some drugs into bones, the environmental conditions during decomposition will determine the 
degree of liquefaction and insect activity on decaying remains.  Significant differences in 
temperature and relative humidity are attributed to divergent sun exposures at the decomposition 
sites as microclimate differences are only seen during daylight hours.  Environment has been 
shown to effect recoveries of drugs from bone tissues, though the results of this study contrast 
previously seen trends.  Distributions across different bones and environments may not be a 
significant factor to consider in drug recoveries for certain drugs, which may reflect a drugs affinity 
for bone.  Future work across distinct microclimates and with different drugs should be undertaken 
to go towards building a database of drug and metabolite responses to aid in interpretations of 
drugs and drug exposure patterns in decomposed skeletal remains. 
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Table A1.1 Microclimate Parameters Temperature, Relative Humidity and Absolute Humidity 
Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-07 10:00 23.51 23.36 52.1 52.6 11.1 11 
2015-07-07 11:00 23.48 23.39 52.7 53.7 11.2 11.2 
2015-07-07 12:00 23.7 23.68 50.6 51.6 10.8 11 
2015-07-07 13:00 23.75 23.68 50.1 50.6 10.7 10.8 
2015-07-07 14:00 23.56 23.53 49.6 50 10.6 10.6 
2015-07-07 15:00 17.78 23.34 73.6 48 11.2 10 
2015-07-07 16:00 17.07 22.04 72.7 54.7 10.6 10.7 
2015-07-07 17:00 16.31 17.12 73.6 70.1 10.3 10.2 
2015-07-07 18:00 15.52 16 71.2 70.6 9.5 9.6 
2015-07-07 19:00 16.54 17.19 67.1 64 9.3 9.3 
2015-07-07 20:00 15.78 16.33 70.7 67.1 9.4 9.3 
2015-07-07 21:00 14.75 14.87 68.6 68.1 8.7 8.6 
2015-07-07 22:00 12.66 13.15 88.5 78.9 9.8 9.1 
2015-07-07 23:00 11.38 10.94 91.8 88.9 9.4 8.9 
2015-07-08 0:00 10.92 10.23 92.6 91 9.3 8.7 
2015-07-08 1:00 11.16 10.11 93.8 94.2 9.4 9 
2015-07-08 2:00 10.77 9.94 95 95.7 9.3 8.9 
2015-07-08 3:00 10.06 9.52 95 96.1 9 8.7 
2015-07-08 4:00 10.01 9.52 96.5 97.2 9 8.8 
2015-07-08 5:00 9.99 8.95 95.7 96.4 8.9 8.5 
2015-07-08 6:00 9.45 9.12 96.8 97.2 8.8 8.6 
2015-07-08 7:00 10.43 10.55 96.5 96.4 9.4 9.4 
2015-07-08 8:00 12.04 13.36 92.2 87.1 9.9 10.1 
2015-07-08 9:00 14.4 17.12 79.9 65.6 9.9 9.6 
2015-07-08 10:00 16.5 20.57 70.2 58.3 9.8 10.4 
2015-07-08 11:00 18.78 22.88 58.4 48.5 9.3 9.9 
2015-07-08 12:00 20.38 24.08 45.9 33.8 8 7.4 
2015-07-08 13:00 22.07 25.75 36.3 29.9 7.1 7.1 
2015-07-08 14:00 23.84 27.15 35.3 29 7.7 7.5 
2015-07-08 15:00 27 27.61 26.2 27.1 6.8 7.2 
2015-07-08 16:00 29.88 27.93 23 28 6.9 7.6 
2015-07-08 17:00 27.98 27.66 25.7 24.4 7 6.5 
2015-07-08 18:00 26.07 25.37 28.5 29.9 6.9 6.9 
2015-07-08 19:00 23.58 22.62 40.3 42.3 8.6 8.4 
2015-07-08 20:00 21.02 20.54 50.1 49 9.1 8.7 
2015-07-08 21:00 18.73 18.12 58.4 57.3 9.3 8.9 
2015-07-08 22:00 17.02 16.83 69.7 65.6 10.2 9.4 
2015-07-08 23:00 16.57 16.24 73.1 68.6 10.2 9.6 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-09 0:00 15.88 15.3 74.6 73.1 10.2 9.5 
2015-07-09 1:00 14.75 14.28 80.9 78 10.3 9.5 
2015-07-09 2:00 14.06 13.8 85 82.2 10.3 9.7 
2015-07-09 3:00 13.46 13.29 86.3 84 10 9.7 
2015-07-09 4:00 12.83 12.76 88 88 9.9 9.9 
2015-07-09 5:00 12.4 12.33 90.6 89.3 10 9.6 
2015-07-09 6:00 12.16 12.11 91.4 91.8 9.8 9.9 
2015-07-09 7:00 12.54 12.83 92.6 90.5 10.2 10.2 
2015-07-09 8:00 14.71 16.31 84.5 73.1 10.7 10.2 
2015-07-09 9:00 16.69 21.19 68.6 52.6 9.8 9.8 
2015-07-09 10:00 18.28 21.64 57.9 48.5 9 9.3 
2015-07-09 11:00 19.3 22.4 55.3 46.4 9.2 9.3 
2015-07-09 12:00 19.95 24.76 56.3 40.8 9.6 9.3 
2015-07-09 13:00 22.98 27.69 38.3 31.9 7.8 8.4 
2015-07-09 14:00 24.64 29.05 34.8 29 7.9 8.4 
2015-07-09 15:00 27.91 29.2 32.9 28 8.9 8.1 
2015-07-09 16:00 29.25 28.65 29.5 30.4 8.5 8.6 
2015-07-09 17:00 28.95 30.18 29 27.6 8.4 8.5 
2015-07-09 18:00 25.54 26.02 35.3 32.8 8.4 8 
2015-07-09 19:00 24.33 24.28 37.3 37.8 8.3 8.4 
2015-07-09 20:00 22.38 21.88 53.7 56.3 10.7 10.7 
2015-07-09 21:00 20.28 19.47 62.5 64.5 10.9 10.8 
2015-07-09 22:00 18.4 17.57 72.7 74.1 11.3 11.1 
2015-07-09 23:00 17.52 16.66 76.6 78.9 11.4 11.2 
2015-07-10 0:00 16.69 15.78 79.9 84.5 11.4 11.2 
2015-07-10 1:00 15.93 14.99 84.1 87.6 11.5 11.1 
2015-07-10 2:00 14.78 14.25 88.9 91 11.3 11 
2015-07-10 3:00 14.64 13.8 91.8 93.8 11.4 11.1 
2015-07-10 4:00 14.3 13.56 91 93.8 11.3 11.1 
2015-07-10 5:00 13.82 13.2 91.4 93.8 10.8 10.8 
2015-07-10 6:00 13.46 12.59 92.6 94.5 10.7 10.4 
2015-07-10 7:00 13.63 13.92 92.6 90.5 11 11 
2015-07-10 8:00 15.5 17.16 81.8 75.6 10.9 11 
2015-07-10 9:00 17.69 21.93 71.7 54.2 10.7 10.6 
2015-07-10 10:00 19.38 24.54 59.9 46.4 10 10.3 
2015-07-10 11:00 20.95 27.57 57.3 38.3 10.5 10.1 
2015-07-10 12:00 23.1 29.38 54.2 38.8 11.3 11.4 
2015-07-10 13:00 26.05 31.22 47.5 35.8 11.5 11.5 
2015-07-10 14:00 27.22 32.03 43.4 33.3 11.2 11.2 
2015-07-10 15:00 29.85 32.5 36.8 30.4 11.1 10.4 
2015-07-10 16:00 32.32 32.42 34.8 32.8 12 11.3 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-10 17:00 29.93 30.76 40.3 38.3 12.2 12.1 
2015-07-10 18:00 28.36 27.76 42.3 43.3 11.7 11.7 
2015-07-10 19:00 26.1 25.97 49 50 11.9 12.1 
2015-07-10 20:00 24.25 24.16 53.2 54.2 11.8 11.8 
2015-07-10 21:00 22.4 22.16 61.5 63 12.3 12.3 
2015-07-10 22:00 21.45 20.85 64.1 66.6 12 12.2 
2015-07-10 23:00 20.21 19.66 71.2 73.6 12.4 12.6 
2015-07-11 0:00 19.23 18.54 75.1 77.5 12.3 12.4 
2015-07-11 1:00 18.59 17.88 77.5 81.3 12.4 12.4 
2015-07-11 2:00 17.88 17.09 80.9 85.4 12.3 12.5 
2015-07-11 3:00 17.21 16.38 85 88.4 12.4 12.3 
2015-07-11 4:00 16.85 16.09 87.6 90.5 12.5 12.3 
2015-07-11 5:00 16.4 15.66 89.8 93 12.5 12.4 
2015-07-11 6:00 16.26 15.54 91.8 94.2 12.8 12.5 
2015-07-11 7:00 16.59 16.66 90.2 91.8 12.9 13.1 
2015-07-11 8:00 17.73 19.16 85.4 80.8 13 13.2 
2015-07-11 9:00 19.64 23.94 77.5 63 13.2 13.7 
2015-07-11 10:00 22 27.74 71.7 52.1 14 14.1 
2015-07-11 11:00 24.45 30.51 61.5 44.4 13.7 13.7 
2015-07-11 12:00 26.63 32.42 55.3 40.3 14 13.8 
2015-07-11 13:00 29 34.27 47 34.8 13.6 13.3 
2015-07-11 14:00 30.63 33.61 43.4 35.3 13.7 13 
2015-07-11 15:00 32.34 33.69 38.3 35.3 13.2 13 
2015-07-11 16:00 33.93 33.79 33.3 33.8 12.5 12.4 
2015-07-11 17:00 32.03 32.73 38.3 34.8 12.9 12.2 
2015-07-11 18:00 30.2 29.73 40.8 42.8 12.6 12.9 
2015-07-11 19:00 27.52 27.52 49 49.5 13 13.1 
2015-07-11 20:00 25.97 25.68 54.7 55.2 13.3 13.1 
2015-07-11 21:00 24.37 23.75 62.5 64 13.9 13.6 
2015-07-11 22:00 22.91 21.95 71.7 74.6 14.6 14.5 
2015-07-11 23:00 22.02 20.95 73.1 78.4 14.3 14.3 
2015-07-12 0:00 21.14 20.02 76.6 82.2 14 14.4 
2015-07-12 1:00 20.4 19.19 83.6 87.1 14.9 14.2 
2015-07-12 2:00 19.71 18.5 85.9 90.1 14.7 14.4 
2015-07-12 3:00 18.92 17.71 87.2 93 14.2 13.9 
2015-07-12 4:00 18.69 17.47 91.4 94.5 14.6 14.1 
2015-07-12 5:00 17.97 16.95 93 95.3 14.2 13.6 
2015-07-12 6:00 17.73 16.78 92.2 95.3 14.1 13.6 
2015-07-12 7:00 17.88 17.83 92.6 94.2 14.1 14.4 
2015-07-12 8:00 19.66 20.85 89.8 84.5 15.3 15.4 
2015-07-12 9:00 21.3 25.49 83.6 66.1 15.6 15.7 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-12 10:00 23.41 28.85 77.5 54.7 16.1 15.5 
2015-07-12 11:00 25.8 32.19 61.5 41.3 14.9 14.2 
2015-07-12 12:00 27.74 33.66 54.2 35.3 14.7 13 
2015-07-12 13:00 29.65 35.38 44.4 30.9 13.1 12.4 
2015-07-12 14:00 31.7 36.37 39.8 28 13.1 12 
2015-07-12 15:00 32.75 35.27 37.8 28 13.3 11.2 
2015-07-12 16:00 33.17 34.74 46.5 32.3 16.7 12.7 
2015-07-12 17:00 31.83 32.73 43.9 36.8 14.8 12.9 
2015-07-12 18:00 30.99 29.83 40.3 43.3 13 13.1 
2015-07-12 19:00 28.36 27.34 48 45.4 13.3 12 
2015-07-12 20:00 26.39 25.93 50.1 50 12.4 12.1 
2015-07-12 21:00 24.11 23.99 65.1 62 14.2 13.5 
2015-07-12 22:00 21.81 21.61 76.1 75.1 14.5 14.3 
2015-07-12 23:00 20.59 20.52 82.7 77 14.8 13.7 
2015-07-13 0:00 20.21 19.73 83.6 78.4 14.6 13.4 
2015-07-13 1:00 19.54 19.02 84.5 82.7 14.1 13.5 
2015-07-13 2:00 18.92 18.5 85.9 85.8 14 13.7 
2015-07-13 3:00 18.07 17.88 87.6 89.7 13.4 13.7 
2015-07-13 4:00 17.16 17.47 89.8 90.5 13.1 13.5 
2015-07-13 5:00 16.59 16.83 90.6 93 12.9 13.3 
2015-07-13 6:00 15.85 16.5 90.6 88.9 12.3 12.4 
2015-07-13 7:00 16.95 18.04 91.4 86.3 13 13.2 
2015-07-13 8:00 18.66 19.76 85 78.4 13.6 13.4 
2015-07-13 9:00 20.97 24.3 75.1 62 13.7 13.8 
2015-07-13 10:00 22.86 27.57 71.7 52.6 14.6 13.9 
2015-07-13 11:00 24.69 29.7 61.5 44.9 14 13.2 
2015-07-13 12:00 25.8 30.63 52.7 38.8 12.8 12.2 
2015-07-13 13:00 28.13 30.73 43.4 34.3 12 10.8 
2015-07-13 14:00 27.76 29.98 42.3 34.3 11.4 10.3 
2015-07-13 15:00 28.58 30.2 42.9 38.8 12.1 12 
2015-07-13 16:00 29.15 30.15 42.3 38.8 12.2 12 
2015-07-13 17:00 27.1 27.74 45.4 42.3 11.8 11.4 
2015-07-13 18:00 27.57 26.95 47.5 46.9 12.6 12.1 
2015-07-13 19:00 25.2 24.95 54.2 54.7 12.6 12.4 
2015-07-13 20:00 23.96 23.96 61 59.9 13.3 13 
2015-07-13 21:00 22.14 22.04 67.6 66.1 13.2 12.9 
2015-07-13 22:00 20.61 20.95 75.6 75.1 13.5 13.7 
2015-07-13 23:00 20.26 20.92 80.4 75.6 14 13.8 
2015-07-14 0:00 19.38 20.26 89.3 87.6 14.9 15.3 
2015-07-14 1:00 19.11 19.95 91.8 95.7 15 16.3 
2015-07-14 2:00 18.57 19.33 93 91.4 14.8 15.3 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-14 3:00 18.04 18.88 93 93.8 14.2 15.3 
2015-07-14 4:00 17.31 18.35 92.6 94.9 13.5 14.8 
2015-07-14 5:00 17.4 18.69 95 95.3 14.2 15.2 
2015-07-14 6:00 17.5 18.76 94.6 95.3 14.1 15.2 
2015-07-14 7:00 17.47 18.76 94.6 94.2 14.1 15 
2015-07-14 8:00 19.59 20.73 92.6 86.3 15.5 15.4 
2015-07-14 9:00 19.92 20.97 86.7 84.9 14.8 15.5 
2015-07-14 10:00 20.68 21.64 85 84 15.2 16 
2015-07-14 11:00 22.6 23.75 78 71.1 15.6 15.1 
2015-07-14 12:00 23.89 25.51 69.2 65 15.1 15.4 
2015-07-14 13:00 20.54 21.35 72.2 70.1 12.9 13.1 
2015-07-14 14:00 18.5 19.07 71.2 68.1 11.4 11.1 
2015-07-14 15:00 18.02 19.16 68.1 64.5 10.4 10.5 
2015-07-14 16:00 18.52 19.9 59.9 55.2 9.6 9.4 
2015-07-14 17:00 18.33 19.57 51.1 49 8 8.2 
2015-07-14 18:00 18.54 19.04 52.7 52.1 8.4 8.5 
2015-07-14 19:00 17.78 18.07 55.3 54.2 8.4 8.3 
2015-07-14 20:00 17.28 17.69 55.8 53.7 8.1 8 
2015-07-14 21:00 15.83 16.14 58.4 57.3 8 7.8 
2015-07-14 22:00 14.35 14.44 63.5 63 7.9 7.8 
2015-07-14 23:00 13.34 13.39 64.1 63.5 7.4 7.3 
2015-07-15 0:00 12.01 12.42 72.2 70.6 7.8 7.8 
2015-07-15 1:00 10.97 11.36 77.1 74.1 7.7 7.6 
2015-07-15 2:00 10.7 10.84 76.1 75.6 7.4 7.6 
2015-07-15 3:00 10.45 10.31 78 80.8 7.6 7.7 
2015-07-15 4:00 9.57 9.37 84.1 85.8 7.6 7.8 
2015-07-15 5:00 9.12 8.95 86.3 87.1 7.6 7.7 
2015-07-15 6:00 8.88 9.03 88 88 7.8 7.8 
2015-07-15 7:00 9.64 10.18 85 83.1 7.9 7.9 
2015-07-15 8:00 10.97 12.01 76.6 72.6 7.7 7.8 
2015-07-15 9:00 13.24 16.07 68.6 54.2 7.9 7.4 
2015-07-15 10:00 15.11 18.76 55.8 45.4 7.3 7.2 
2015-07-15 11:00 16.97 21.21 52.7 40.3 7.7 7.5 
2015-07-15 12:00 18.83 23.8 49 34.8 7.8 7.4 
2015-07-15 13:00 21.19 26.27 41.8 28.5 7.8 7.1 
2015-07-15 14:00 23.43 27.74 33.3 25.7 6.9 7 
2015-07-15 15:00 26.88 28.18 28.1 24.8 7.1 6.9 
2015-07-15 16:00 29.05 28.31 23.9 23 6.9 6.4 
2015-07-15 17:00 28.08 29.33 25.7 22.1 7 6.5 
2015-07-15 18:00 25.54 26.05 29.5 27.6 7 6.7 
2015-07-15 19:00 23 23.17 33.8 31.9 6.9 6.6 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-15 20:00 20.99 21.88 51.6 34.8 9.4 6.6 
2015-07-15 21:00 17.52 19.49 62 48 9.3 8 
2015-07-15 22:00 15.83 16.76 72.7 67.6 9.9 9.6 
2015-07-15 23:00 16.09 15.54 71.2 70.6 9.7 9.4 
2015-07-16 0:00 15.33 14.11 71.2 74.6 9.3 9 
2015-07-16 1:00 14.16 13.07 79.4 81.7 9.6 9.2 
2015-07-16 2:00 13.03 12.21 84.5 86.3 9.5 9.3 
2015-07-16 3:00 12.28 11.53 87.6 91 9.4 9.3 
2015-07-16 4:00 11.36 11.36 90.2 92.6 9.2 9.5 
2015-07-16 5:00 10.97 11.41 91.8 92.6 9.2 9.5 
2015-07-16 6:00 10.53 11.11 94.2 95.7 9.2 9.6 
2015-07-16 7:00 11.53 12.95 95.7 94.9 9.8 10.7 
2015-07-16 8:00 14.18 16.4 91.8 81.7 11.1 11.4 
2015-07-16 9:00 16.69 21.95 80.4 59.4 11.5 11.6 
2015-07-16 10:00 19.02 25.56 70.2 47.4 11.5 11.3 
2015-07-16 11:00 21.02 29.1 50.6 32.3 9.2 9.3 
2015-07-16 12:00 23 30.13 46.5 28 9.5 8.6 
2015-07-16 13:00 26.19 30.51 38.3 26.2 9.5 8.1 
2015-07-16 14:00 26.98 29.93 33.3 25.3 8.6 7.6 
2015-07-16 15:00 29.55 29.65 28.5 25.3 8.4 7.5 
2015-07-16 16:00 31.37 29.2 24.8 23.9 8.2 6.9 
2015-07-16 17:00 28.11 28.36 27.1 24.8 7.3 6.9 
2015-07-16 18:00 26.17 24.66 29 29.9 7.2 6.8 
2015-07-16 19:00 22.93 22.28 40.8 40.8 8.3 8 
2015-07-16 20:00 20.8 20.71 48.5 48 8.9 8.6 
2015-07-16 21:00 18.64 18.95 59.9 57.8 9.6 9.4 
2015-07-16 22:00 16.45 16.62 70.7 69.1 9.9 9.9 
2015-07-16 23:00 15.83 15.38 74.6 75.6 10.2 9.8 
2015-07-17 0:00 14.52 14.85 80.9 81.3 10 10.3 
2015-07-17 1:00 13.65 14.4 84.5 84 10 10.4 
2015-07-17 2:00 14.25 15.57 83.2 76 10.1 10.1 
2015-07-17 3:00 13.96 14.85 81.8 75.6 9.9 9.6 
2015-07-17 4:00 13.48 14.23 81.8 76.5 9.5 9.3 
2015-07-17 5:00 14.06 14.56 89.8 88.4 10.9 11 
2015-07-17 6:00 14.59 15.4 89.3 85.8 11.1 11.2 
2015-07-17 7:00 15.33 16.09 85.9 82.7 11.2 11.3 
2015-07-17 8:00 15.83 16.66 81.8 78.4 11.1 11.2 
2015-07-17 9:00 16.16 16.93 80.9 77 11 11 
2015-07-17 10:00 16.64 17.64 81.3 77.5 11.6 11.6 
2015-07-17 11:00 16.43 17.04 87.6 84.5 12.2 12.3 
2015-07-17 12:00 16 16.45 91 91.8 12.4 12.8 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-17 13:00 15.52 16.21 94.2 95.3 12.5 13.3 
2015-07-17 14:00 15.35 15.83 96.5 97.5 12.5 13.3 
2015-07-17 15:00 15.45 15.95 97.2 97.9 12.9 13.3 
2015-07-17 16:00 15.81 16.5 97.6 97.9 13 13.6 
2015-07-17 17:00 16.09 17.02 97.6 97.9 13.3 14.3 
2015-07-17 18:00 16.19 17.04 97.6 97.5 13.3 14.2 
2015-07-17 19:00 16.33 17.28 97.6 96.4 13.6 14.1 
2015-07-17 20:00 16.33 17.19 97.6 96.4 13.6 14.1 
2015-07-17 21:00 16.31 17.07 97.9 97.2 13.6 14.2 
2015-07-17 22:00 16.45 17.21 97.9 98.2 13.6 14.3 
2015-07-17 23:00 16.47 17.02 97.9 98.2 13.6 14.3 
2015-07-18 0:00 16.47 16.97 97.9 97.9 13.6 14.3 
2015-07-18 1:00 16.59 16.95 98.3 98.2 14 14 
2015-07-18 2:00 16.62 16.9 97.9 97.9 14 14 
2015-07-18 3:00 16.59 16.83 97.6 97.9 13.9 14 
2015-07-18 4:00 16 15.69 97.6 98.9 13.3 13.2 
2015-07-18 5:00 16.04 16.19 98.3 99.9 13.4 13.6 
2015-07-18 6:00 16.31 16.62 99 99.6 13.8 14.2 
2015-07-18 7:00 16.83 17.14 99 98.6 14.1 14.4 
2015-07-18 8:00 17.52 18.5 96.8 96.4 14.4 15.4 
2015-07-18 9:00 18.95 22.24 93 83.1 15.2 16.2 
2015-07-18 10:00 20.4 25.88 88.5 72.1 15.8 17.5 
2015-07-18 11:00 22.26 26.07 84.5 70.1 16.5 17 
2015-07-18 12:00 21.95 23.48 85.4 77.5 16.7 16.5 
2015-07-18 13:00 21.95 23.63 83.6 77 16.3 16.4 
2015-07-18 14:00 22.81 24.47 80.9 74.1 16.5 16.5 
2015-07-18 15:00 22.74 24.47 82.2 75.6 16.8 16.8 
2015-07-18 16:00 23.68 25.88 78.5 69.6 16.7 16.9 
2015-07-18 17:00 23.56 25.1 84.5 74.6 18 17.3 
2015-07-18 18:00 24.64 26.02 76.1 70.1 17.3 17 
2015-07-18 19:00 23.77 24.83 80.9 76 17.2 17.3 
2015-07-18 20:00 22.64 23.29 85.9 82.7 17.1 17.2 
2015-07-18 21:00 21.71 21.95 88.5 88.4 16.9 17.2 
2015-07-18 22:00 21.07 21.78 93 92.2 17 17.6 
2015-07-18 23:00 21.14 21.54 93.8 93.4 17.1 17.8 
2015-07-19 0:00 20.42 20.83 94.6 94.5 16.9 17.3 
2015-07-19 1:00 19.33 19.57 93.4 93.8 15.6 15.7 
2015-07-19 2:00 17.76 18.04 93.8 97.2 14.3 14.8 
2015-07-19 3:00 17.09 17.43 95.7 98.2 14 14.7 
2015-07-19 4:00 16.71 17.52 96.5 99.6 13.8 14.9 
2015-07-19 5:00 16.85 17.26 97.2 99.3 13.9 14.5 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-19 6:00 16.64 17.43 96.8 99.9 13.8 14.9 
2015-07-19 7:00 17.81 18.47 99 99.3 15.1 15.5 
2015-07-19 8:00 19.35 20.85 98.3 91.8 16.4 16.8 
2015-07-19 9:00 21.45 23.75 89.3 81.3 16.7 17.3 
2015-07-19 10:00 22.62 26.53 84.1 72.6 16.8 18 
2015-07-19 11:00 24.01 29.65 81.3 57.8 17.7 17.1 
2015-07-19 12:00 25.97 31.19 73.6 51.1 17.9 16.4 
2015-07-19 13:00 27.49 32.14 57.3 43.3 15.2 14.6 
2015-07-19 14:00 27.39 30.23 54.7 42.8 14.5 13.2 
2015-07-19 15:00 26.93 28.6 52.1 44.9 13.2 12.7 
2015-07-19 16:00 28.58 29.93 45.4 39.8 12.8 12 
2015-07-19 17:00 26.83 29.18 41.3 34.8 10.5 10 
2015-07-19 18:00 27.66 27.17 36.8 37.8 9.7 9.8 
2015-07-19 19:00 25.12 25 41.3 41.8 9.6 9.7 
2015-07-19 20:00 23.41 23.27 43.9 43.3 9.1 9 
2015-07-19 21:00 21.61 20.57 48.5 52.1 9.3 9.3 
2015-07-19 22:00 18.85 17.62 67.6 66.1 10.8 9.9 
2015-07-19 23:00 17.52 17.07 71.7 68.6 10.7 10 
2015-07-20 0:00 17.95 17.04 75.6 79.4 11.5 11.6 
2015-07-20 1:00 17.31 16.24 79 84 11.5 11.7 
2015-07-20 2:00 16.74 15.71 83.2 88 11.9 11.7 
2015-07-20 3:00 16.31 15.26 84.1 89.7 11.7 11.7 
2015-07-20 4:00 15.85 14.9 85.4 90.5 11.6 11.5 
2015-07-20 5:00 15.33 14.4 88.9 93.4 11.6 11.6 
2015-07-20 6:00 14.92 14.78 92.6 94.9 11.8 12.1 
2015-07-20 7:00 15.76 16.24 91.8 91.4 12.2 12.7 
2015-07-20 8:00 17.38 18.66 87.6 83.1 13.1 13.3 
2015-07-20 9:00 20.07 24.45 79.4 60.9 13.9 13.5 
2015-07-20 10:00 22.07 28.03 74.1 50.6 14.5 13.7 
2015-07-20 11:00 25 31.11 61.5 40.8 14.3 13.1 
2015-07-20 12:00 25.44 28.88 56.3 44.9 13.4 12.7 
2015-07-20 13:00 26.29 27.98 52.7 45.4 13.1 12.3 
2015-07-20 14:00 29.43 32.78 44.4 36.3 13.1 12.7 
2015-07-20 15:00 26.85 29.28 52.1 44.9 13.2 13 
2015-07-20 16:00 27 28.16 54.2 49.5 14 13.7 
2015-07-20 17:00 23.72 24.66 76.1 75.1 16.2 17.1 
2015-07-20 18:00 24.83 24.64 59.9 60.9 13.6 13.8 
2015-07-20 19:00 24.28 23.92 60.5 62.5 13.5 13.6 
2015-07-20 20:00 23.12 22.93 62 63.5 12.9 12.9 
2015-07-20 21:00 21.52 21.23 70.2 70.1 13.1 13.1 
2015-07-20 22:00 20.33 19.38 75.1 78 13.1 13 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-20 23:00 19.3 18.12 76.1 80.8 12.7 12.6 
2015-07-21 0:00 18.28 16.83 77.5 83.1 12.1 11.8 
2015-07-21 1:00 17.26 15.95 79.4 84.5 11.6 11.5 
2015-07-21 2:00 16.07 15.38 83.2 84.9 11.3 11 
2015-07-21 3:00 15.45 14.47 86.3 89.3 11.5 11.1 
2015-07-21 4:00 15.71 15.33 85.9 88.9 11.4 11.6 
2015-07-21 5:00 15.19 14.47 87.6 91 11.4 11.3 
2015-07-21 6:00 15.19 15.02 85 87.1 11.1 11.1 
2015-07-21 7:00 15.3 15.16 82.7 84.9 10.8 11 
2015-07-21 8:00 15.83 16.45 76.1 77.5 10.4 10.8 
2015-07-21 9:00 16.4 18.31 72.2 65 10.1 10.1 
2015-07-21 10:00 18.4 20.42 63 54.7 9.8 9.8 
2015-07-21 11:00 19.95 25.27 54.7 40.3 9.3 9.4 
2015-07-21 12:00 21.95 28.36 45.4 30.4 8.9 8.4 
2015-07-21 13:00 24.33 28.33 38.8 30.4 8.6 8.4 
2015-07-21 14:00 26.46 30.25 32.9 25.3 8.2 7.8 
2015-07-21 15:00 27.12 29.38 30.9 25.3 8 7.5 
2015-07-21 16:00 24.93 26.44 36.3 30.4 8.3 7.5 
2015-07-21 17:00 24.62 26.56 45.9 34.8 10.4 8.8 
2015-07-21 18:00 24.23 25.8 36.8 33.3 8.2 8.1 
2015-07-21 19:00 23.22 23.99 36.8 33.8 7.7 7.4 
2015-07-21 20:00 22.14 22.69 35.8 35.3 7 7.2 
2015-07-21 21:00 20.21 19.85 37.3 38.8 6.5 6.6 
2015-07-21 22:00 17.95 17.19 50.6 48 7.7 7 
2015-07-21 23:00 16.78 15.88 52.7 54.2 7.5 7.4 
2015-07-22 0:00 15.42 14.52 62.5 60.9 8.1 7.6 
2015-07-22 1:00 14.49 13.68 65.1 66.1 8.1 7.8 
2015-07-22 2:00 14.18 13.39 69.7 71.6 8.4 8.3 
2015-07-22 3:00 13.48 12.95 76.6 78.9 8.9 8.9 
2015-07-22 4:00 13.68 13.39 76.1 78.4 9 9.1 
2015-07-22 5:00 14.11 13.96 73.1 74.1 8.9 9 
2015-07-22 6:00 14.71 14.85 69.7 69.1 8.9 8.8 
2015-07-22 7:00 14.32 14.3 72.7 73.1 9 9.1 
2015-07-22 8:00 15.04 16 69.7 67.6 8.9 9.2 
2015-07-22 9:00 16.71 22 66.1 46.4 9.4 9 
2015-07-22 10:00 18.31 23.22 57.9 43.3 9 9 
2015-07-22 11:00 19.66 23.34 53.2 42.3 9.1 8.8 
2015-07-22 12:00 22 26.36 47 35.3 9.2 8.8 
2015-07-22 13:00 24.28 28.23 37.3 28 8.3 7.7 
2015-07-22 14:00 25.58 28.4 32.9 27.1 7.8 7.5 
2015-07-22 15:00 26.85 29.1 30 25.3 7.6 7.3 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-22 16:00 25 25.93 33.3 30.4 7.7 7.4 
2015-07-22 17:00 23.89 25.08 36.3 32.8 7.9 7.6 
2015-07-22 18:00 23.72 24.3 37.8 34.8 8 7.7 
2015-07-22 19:00 22.72 23.1 34.8 35.3 7.1 7.4 
2015-07-22 20:00 21.57 21.69 36.3 36.3 6.9 6.9 
2015-07-22 21:00 19.47 19.61 48 43.8 8 7.3 
2015-07-22 22:00 16.28 16 63 60.4 8.8 8.2 
2015-07-22 23:00 14.95 14.37 71.2 72.6 9 9 
2015-07-23 0:00 13.89 13.41 75.1 72.1 8.9 8.3 
2015-07-23 1:00 13.53 13.05 78 84 9.2 9.5 
2015-07-23 2:00 12.35 11.67 78.5 84.9 8.4 8.9 
2015-07-23 3:00 12.79 12.13 82.2 84.9 9.3 9.1 
2015-07-23 4:00 13.34 13.56 79.4 74.6 9.2 8.8 
2015-07-23 5:00 12.69 12.47 81.3 78 9 8.6 
2015-07-23 6:00 12.11 11.65 84.5 83.6 9.1 8.8 
2015-07-23 7:00 13.56 13.94 79.9 77.5 9.5 9.4 
2015-07-23 8:00 15.04 16.62 77.5 69.6 9.8 9.9 
2015-07-23 9:00 17.14 19.76 71.7 56.8 10.5 9.7 
2015-07-23 10:00 19.33 26.85 57.3 35.8 9.6 9.1 
2015-07-23 11:00 22 29.33 39.8 25.7 7.8 7.6 
2015-07-23 12:00 23.72 30.91 31.9 21.7 6.8 6.8 
2015-07-23 13:00 26.61 32.47 26.7 18.3 6.8 6.3 
2015-07-23 14:00 27.32 32.55 26.2 18.7 6.8 6.4 
2015-07-23 15:00 31.57 34.19 20 16.2 6.6 6.1 
2015-07-23 16:00 31.01 32.57 21.7 19.1 7 6.7 
2015-07-23 17:00 27.44 29.5 25.3 22.1 6.7 6.5 
2015-07-23 18:00 29.03 28.75 23 22.6 6.6 6.4 
2015-07-23 19:00 26.8 26.88 26.7 26.2 6.8 6.6 
2015-07-23 20:00 24.08 24.08 37.3 37.3 8.1 8.1 
2015-07-23 21:00 21.5 21.04 45.9 43.3 8.6 7.9 
2015-07-23 22:00 19.71 19.04 50.6 49 8.6 8 
2015-07-23 23:00 18.73 17.92 56.3 55.2 9 8.4 
2015-07-24 0:00 17.26 16.26 63.5 64 9.3 8.9 
2015-07-24 1:00 16.35 15.42 66.6 70.1 9.3 9.1 
2015-07-24 2:00 15.14 14.08 74.1 76.5 9.6 9.3 
2015-07-24 3:00 14.61 13.53 77.5 80.8 9.6 9.6 
2015-07-24 4:00 14.59 13.68 78 82.2 9.7 9.7 
2015-07-24 5:00 14.04 12.76 83.2 86.7 10.1 9.8 
2015-07-24 6:00 13.48 12.37 84.1 87.6 9.7 9.7 
2015-07-24 7:00 13.75 13.72 85.4 84.5 10.1 10 
2015-07-24 8:00 15.83 16.9 78 73.6 10.6 10.5 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-24 9:00 18.07 25 71.7 44.4 10.9 10.3 
2015-07-24 10:00 20.33 28.95 61 35.3 10.7 10.2 
2015-07-24 11:00 23.24 32.11 50.1 28.5 10.4 9.6 
2015-07-24 12:00 25.71 33.66 38.8 21.7 9.2 8 
2015-07-24 13:00 30.05 34.74 28.1 19.5 8.5 7.6 
2015-07-24 14:00 30.48 35.33 26.7 18.3 8.2 7.3 
2015-07-24 15:00 32.96 35.94 20.8 16.6 7.3 7 
2015-07-24 16:00 36.4 35.62 16.6 15.8 7.1 6.5 
2015-07-24 17:00 33.27 34.69 19.5 17 7 6.7 
2015-07-24 18:00 31.78 31.14 24.4 23 8.2 7.4 
2015-07-24 19:00 26.76 26.73 45.4 44.9 11.5 11.4 
2015-07-24 20:00 24.83 25.05 53.7 53.7 12.2 12.5 
2015-07-24 21:00 23.48 23.82 59.9 58.9 12.8 12.5 
2015-07-24 22:00 22.31 22.72 65.6 65 13.1 13.2 
2015-07-24 23:00 20.92 21.21 72.7 72.6 13.3 13.5 
2015-07-25 0:00 19.42 19.76 79 78.9 13.2 13.5 
2015-07-25 1:00 18.5 18.8 83.6 83.1 13.3 13.3 
2015-07-25 2:00 17.64 18.02 86.3 86.7 12.9 13.2 
2015-07-25 3:00 18.31 19.09 85.4 84 13.3 13.7 
2015-07-25 4:00 18.35 19.26 88 86.3 13.7 14.4 
2015-07-25 5:00 18.78 19.49 86.3 84 13.8 14 
2015-07-25 6:00 18.26 18.88 90.6 89.3 14.1 14.6 
2015-07-25 7:00 18.28 19.19 91.8 87.1 14.3 14.2 
2015-07-25 8:00 18.99 19.71 89.3 86.3 14.6 14.7 
2015-07-25 9:00 19.14 19.95 93 93 15.2 15.9 
2015-07-25 10:00 18.78 19.57 95.7 95.7 15.3 16 
2015-07-25 11:00 17.85 18 99.3 99.9 15.2 15.2 
2015-07-25 12:00 19.73 20.52 100 98.2 17.1 17.5 
2015-07-25 13:00 22.57 24.18 98.6 79.9 19.7 17.4 
2015-07-25 14:00 22.64 24.01 93 79.9 18.5 17.4 
2015-07-25 15:00 26.07 28.13 77.5 66.6 18.8 18.4 
2015-07-25 16:00 28.85 30.2 58.9 53.1 16.6 16.4 
2015-07-25 17:00 28.4 30.76 53.7 46.4 14.8 14.6 
2015-07-25 18:00 26.02 27.66 58.9 53.1 14.3 14.1 
2015-07-25 19:00 26.05 26.12 53.7 53.7 13 13 
2015-07-25 20:00 24.37 24.83 63 58.9 14 13.4 
2015-07-25 21:00 21.9 21.83 77.5 68.6 14.8 13.1 
2015-07-25 22:00 19.61 19.66 83.6 77.5 14 13.2 
2015-07-25 23:00 18.45 18.69 87.2 82.7 13.6 13.2 
2015-07-26 0:00 17.54 18.14 91 90.1 13.6 14.1 
2015-07-26 1:00 17.12 17.57 93 89.3 13.6 13.3 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-26 2:00 17.81 17.66 89.8 88 13.7 13.1 
2015-07-26 3:00 16.88 16.76 91.8 91 13.1 13 
2015-07-26 4:00 16.5 16.47 92.6 92.2 12.9 12.8 
2015-07-26 5:00 16.04 15.97 93.8 92.2 12.8 12.6 
2015-07-26 6:00 15.95 15.59 94.2 93.8 12.8 12.5 
2015-07-26 7:00 16.4 16.59 95 94.9 13.2 13.5 
2015-07-26 8:00 17.9 19.28 92.2 85.4 14.1 14.3 
2015-07-26 9:00 19.85 25.61 84.1 59.9 14.4 14.2 
2015-07-26 10:00 21.97 28.78 74.6 48 14.5 13.6 
2015-07-26 11:00 24.45 31.67 68.6 42.3 15.3 13.9 
2015-07-26 12:00 26.32 33.48 54.2 37.3 13.4 13.7 
2015-07-26 13:00 29.6 34.29 41.8 32.3 12.3 12.4 
2015-07-26 14:00 30.96 35.01 40.3 30.4 13 11.9 
2015-07-26 15:00 31.75 34.72 39.8 31.4 13.4 12.3 
2015-07-26 16:00 31.9 33.01 36.3 33.3 12.2 12 
2015-07-26 17:00 29.95 30.99 38.3 34.3 11.5 11 
2015-07-26 18:00 26.68 27.42 49 48 12.4 12.7 
2015-07-26 19:00 25.54 26.71 52.7 50 12.5 12.7 
2015-07-26 20:00 24.04 24.25 57.3 59.9 12.5 13.3 
2015-07-26 21:00 22.12 22.28 80.9 83.6 15.8 16.3 
2015-07-26 22:00 20.16 20.64 90.2 86.3 15.8 15.4 
2015-07-26 23:00 18.95 19.88 91.8 85.8 15 14.7 
2015-07-27 0:00 18.66 19.26 92.6 87.6 14.8 14.6 
2015-07-27 1:00 18.88 18.78 90.2 90.5 14.7 14.5 
2015-07-27 2:00 18.4 18.04 89.8 92.2 14 14.1 
2015-07-27 3:00 17.66 17.45 91.8 93.8 13.7 14 
2015-07-27 4:00 17.16 16.85 93.4 94.5 13.6 13.5 
2015-07-27 5:00 17.04 16.66 93.4 94.9 13.6 13.5 
2015-07-27 6:00 16.76 16.26 94.6 96.8 13.5 13.5 
2015-07-27 7:00 17.02 17.31 95.7 95.7 14 14 
2015-07-27 8:00 18.57 20.02 93 87.6 14.8 15.3 
2015-07-27 9:00 20.68 26.44 84.5 62 15.1 15.4 
2015-07-27 10:00 23 30.2 75.6 49.5 15.4 15.3 
2015-07-27 11:00 24.93 32.39 68.1 41.8 15.5 14.4 
2015-07-27 12:00 27.02 34.4 60.5 39.3 15.7 15.1 
2015-07-27 13:00 30.48 35.92 45.9 29 14.1 11.9 
2015-07-27 14:00 30.05 33.69 43.4 33.8 13.1 12.4 
2015-07-27 15:00 33.25 35.49 35.8 29.5 12.9 11.8 
2015-07-27 16:00 31.09 32.03 50.6 33.3 16.3 11.2 
2015-07-27 17:00 34.27 35.92 25.7 21.7 9.9 8.9 
2015-07-27 18:00 32.68 32.81 28.5 27.6 10 9.7 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-27 19:00 30.91 31.24 33.3 32.8 10.5 10.6 
2015-07-27 20:00 28.6 28.55 44.9 44.9 12.7 12.7 
2015-07-27 21:00 26.22 25.49 54.2 56.3 13.4 13.4 
2015-07-27 22:00 24.21 23.22 61.5 63.5 13.4 13.2 
2015-07-27 23:00 21.95 22.33 75.1 66.1 14.6 13.2 
2015-07-28 0:00 20.97 21.11 77.5 73.6 14.1 13.4 
2015-07-28 1:00 20.85 20.99 79 77 14.4 14.1 
2015-07-28 2:00 20.11 19.88 80.9 80.8 14.1 13.8 
2015-07-28 3:00 19.59 19.68 84.1 84 14 14.3 
2015-07-28 4:00 19.26 19.3 86.3 84.5 14.4 14.1 
2015-07-28 5:00 19.09 18.95 87.2 87.1 14.2 14.2 
2015-07-28 6:00 18.78 18.54 88.9 88.4 14.2 14.1 
2015-07-28 7:00 19.35 19.49 88 88.4 14.7 14.8 
2015-07-28 8:00 20.57 22.88 85.9 75.6 15.3 15.4 
2015-07-28 9:00 22.79 29.03 81.8 50.6 16.7 14.6 
2015-07-28 10:00 25.27 32.88 67.1 42.3 15.6 14.9 
2015-07-28 11:00 27.66 35.65 59.9 35.3 15.9 14.5 
2015-07-28 12:00 29.53 36.73 53.7 33.3 15.8 14.3 
2015-07-28 13:00 33.45 38.07 40.3 31.9 14.8 14.6 
2015-07-28 14:00 34.16 38.52 39.3 29.5 14.7 13.8 
2015-07-28 15:00 36.13 38.94 32.4 26.2 13.6 12.6 
2015-07-28 16:00 38.82 39.08 27.6 26.2 13.2 12.8 
2015-07-28 17:00 36.08 38.29 28.1 23.9 11.8 11.2 
2015-07-28 18:00 34.53 34.53 32.4 32.8 12.4 12.6 
2015-07-28 19:00 31.06 30.99 40.8 40.8 13.1 13.1 
2015-07-28 20:00 29.03 28.85 47.5 49 13.7 13.8 
2015-07-28 21:00 26.76 26.07 55.8 54.7 14.1 13.3 
2015-07-28 22:00 24.23 24.49 67.6 60.4 15 13.4 
2015-07-28 23:00 22.5 23.07 74.6 68.6 14.9 14.3 
2015-07-29 0:00 22.93 22.55 69.7 70.6 14.2 14.1 
2015-07-29 1:00 21.54 21.59 79 75.6 15.1 14.4 
2015-07-29 2:00 20.85 20.95 81.8 78.4 14.9 14.3 
2015-07-29 3:00 20.71 21.11 84.1 79.9 15 14.6 
2015-07-29 4:00 20.23 20.8 85.4 81.3 14.9 14.8 
2015-07-29 5:00 19.47 20.38 88 84.9 14.7 14.8 
2015-07-29 6:00 18.45 19.3 88.9 87.6 13.9 14.6 
2015-07-29 7:00 19.68 20.35 88.5 86.3 15.1 15.1 
2015-07-29 8:00 20.42 22.86 84.5 75.1 15.1 15.3 
2015-07-29 9:00 22.81 27.39 71.7 52.1 14.6 13.8 
2015-07-29 10:00 25.22 32.03 62.5 41.3 14.5 13.9 
2015-07-29 11:00 27.74 33.53 54.7 38.3 14.8 14.1 
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Date/Time: 
Site A Low 
Temp (°C) 
Site B Low 
Temp (°C) 
Site A Low 
RH (%) 
Site B Low 
RH (%) 
Site A Low 
AH (g/m3) 
Site B Low 
AH (g/m3) 
2015-07-29 12:00 29.45 34.03 49 36.3 14.5 13.6 
2015-07-29 13:00 32.7 34.53 39.8 32.8 14 12.6 
2015-07-29 14:00 33.27 34.32 37.8 32.3 13.6 12.4 
2015-07-29 15:00 33.59 33.93 33.8 29.9 12.4 11.2 
2015-07-29 16:00 33.98 33.95 30 30.4 11.3 11.4 
2015-07-29 17:00 29.15 29.65 39.8 39.3 11.5 11.6 
2015-07-29 18:00 27.29 27.69 49.6 48.5 12.8 12.8 
2015-07-29 19:00 25.41 25.93 61 60.4 14.5 14.7 
2015-07-29 20:00 20.64 21.21 96.5 96.4 17.2 18 
2015-07-29 21:00 20.45 21.11 96.8 93.4 17.3 17 
2015-07-29 22:00 19.61 20.14 97.2 96.4 16.2 16.8 
2015-07-29 23:00 19.19 19.28 97.6 95.3 15.9 15.9 
2015-07-30 0:00 17.9 18 95.4 91.4 14.6 14 
2015-07-30 1:00 17.28 17.24 93.8 94.5 13.7 13.8 
2015-07-30 2:00 16.69 16.59 96.5 95.7 13.8 13.6 
2015-07-30 3:00 16.26 16.21 95.7 93.8 13.3 13.1 
2015-07-30 4:00 15.73 16 96.1 93 12.8 12.7 
2015-07-30 5:00 15.04 16.12 96.1 91.4 12.2 12.4 
2015-07-30 6:00 15.16 16.04 97.6 92.6 12.7 12.6 
2015-07-30 7:00 16.12 17.47 97.2 88.9 13.2 13.3 
2015-07-30 8:00 17.62 20.14 90.6 78.9 13.5 13.8 
2015-07-30 9:00 19.3 23.77 87.2 66.6 14.6 14.2 
2015-07-30 10:00 20.99 26.63 76.1 57.3 13.9 14.5 
2015-07-30 11:00 22.5 28.48 71.2 50 14.2 13.8 
2015-07-30 12:00 23.31 28.18 59.9 46.4 12.5 12.8 
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Appendix II: 
Drug Responses 
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Table A2.1 Control Animal Drug Responses 
Bone Type: Animal: Mass (g):  DXM d3-DXM DXT d3-DXT DXT 150 d3-DXT 153 dmDXT 
VERT Ctrl A-1 0.204  1716 141471 0 134236 7752 126979 0 
VERT Ctrl A-2 0.2039  2859 142945 681 130315 13610 122677 0 
FEMUR Ctrl A-1 0.198  1417 89769 850 74467 15701 166445 0 
FEMUR Ctrl A-2 0.196  1799 85927 1221 78447 7930 170960 0 
RIB Ctrl A-1 0.2106  1388 41603 265 42254 8416 100956 0 
RIB Ctrl A-2 0.2119  231 39920 1449 53576 6261 121141 291 
TIBIA Ctrl A-1 0.2193  6726 128861 0 141158 38142 196543 0 
TIBIA Ctrl A-2 0.2003  1036 61853 0 55397 9720 162383 0 
PELVIS Ctrl A-1 0.1988  9962 177824 0 98787 10820 293815 0 
PELVIS Ctrl A-2 0.2146  6715 210354 0 151053 17044 362615 0 
SKULL Ctrl A-1 0.2085  12815 52128 0 73730 8737 85990 322 
SKULL Ctrl A-2 0.2135  17078 80559 0 103659 9455 136468 626 
SCAPULA Ctrl A-1 0.121  0 177737 0 79168 16547 344016 0 
SCAPULA Ctrl A-2 0.1095  632 132160 0 83693 10507 267657 0 
BLOOD Ctrl A-1 0.25  1217 56380 1489 27364 15397 62930 0 
BLOOD Ctrl A-2 0.25  268 51307 177 15592 19450 43460 0 
VERT Ctrl B-1 0.2078  0 299658 0 382241 98874 457512 0 
VERT Ctrl B-2 0.2129  0 292104 0 320780 116680 442971 0 
FEMUR Ctrl B-1 0.2013  2307 149603 2267 163701 25845 238543 0 
FEMUR Ctrl B-2 0.1922  8751 171750 3249 178190 36796 235336 0 
RIB Ctrl B-1 0.1935  2186 57660 747 54622 5980 108505 796 
RIB Ctrl B-2 0.2101  3704 89193 356 80747 5010 165391 510 
TIBIA Ctrl B-1 0.1982  3950 170589 0 235366 95684 402045 0 
TIBIA Ctrl B-2 0.2132  0 188437 0 204345 18192 272166 0 
PELVIS Ctrl B-1 0.2024  13510 469176 0 169363 42288 465028 0 
PELVIS Ctrl B-2 0.2108  10077 200758 0 486259 101643 221136 0 
SKULL Ctrl B-1 0.2087  78154 96782 4152 336561 139654 223332 2720 
SKULL Ctrl B-2 0.2111  12919 317376 3238 108946 27711 470982 2237 
 
 
77 
 
Bone Type: Animal: Mass (g):  DXM d3-DXM DXT d3-DXT DXT 150 d3-DXT 153 dmDXT 315 
SCAPULA Ctrl B-1 0.1129  312 102255 0 428484 60710 197889 0 
SCAPULA Ctrl B-2 0.1052  4823 200745 0 56910 11731 294651 0 
BLOOD Ctrl B-1 0.25  906 64615 417 14530 5735 52130 0 
BLOOD Ctrl B-2 0.25  561 43841 327 29061 5225 82352 0 
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Table A2.2: Drug Responses Following Acute DXM (75 mg/kg) Administrations 
Bone Type: Animal: Mass (g):  DXM d3-DXM DXT d3-DXT DXT 150 d3-DXT 153 dmDXT 
VERT Acu A-1 0.2003   1783727 384820 282935 327484 387763 392702 381235 
VERT Acu A-2 0.2081  2339929 330909 193846 390081 483373 359498 312805 
VERT Acu A-3 0.2053  580940 338067 177453 455348 172959 463850 328313 
VERT Acu A-4 0.213   838039 269173 56590 313240 75678 398862 70184 
VERT Acu A-5 0.2324   2766437 360644 1061047 323231 1079752 413445 650164 
FEMUR Acu A-1 0.1979   651196 285612 76710 290977 127852 394005 22298 
FEMUR Acu A-2 0.2163  700739 246434 125029 280497 161624 527395 40643 
FEMUR Acu A-3 0.1933  214142 146762 28494 164532 107391 328588 2549 
FEMUR Acu A-4 0.1981   857382 292203 16609 243366 81202 381523 5210 
FEMUR Acu A-5 0.2049   738954 231726 7289 235869 143027 329193 31356 
RIB Acu A-1 0.2007   936395 177348 n/a 217159 290799 356757 142291 
RIB Acu A-2 0.2099  2322787 268094 834387 368328 1041087 649098 210042 
RIB Acu A-3 0.1977  275337 379817 n/a 399640 85117 596569 74759 
RIB Acu A-4 0.205   1064064 283732 n/a  322834 48062 512533 65798 
RIB Acu A-5 0.1953   916555 162771 518117 216219 821118 471682 384480 
TIBIA Acu A-1 0.2025   1794655 270662 n/a 239603 248482 345625 66446 
TIBIA Acu A-2 0.2138  592501 151913 n/a 121745 146248 270256 27223 
TIBIA Acu A-3 0.1993  790670 249553 133564 268326 228844 567462 n/a 
TIBIA Acu A-4 0.2089   1931559 307369 n/a 339134 107238 493320 n/a 
TIBIA Acu A-5 0.1971   922853 207367 139554 232471 183956 393234 n/a 
PELVIS Acu A-1 0.2014   744165 163603 n/a 381993 241347 244301 106361 
PELVIS Acu A-2 0.2  657135 246855 n/a 463485 224634 568979 106760 
PELVIS Acu A-3 0.2053  629080 393950 108105 152340 188451 469978 10443 
PELVIS Acu A-4 0.1919  276843 234192 n/a 107120 27499 358016 4820 
PELVIS Acu A-5 0.2099   944679 140456 110769 159117 388140 224225 84932 
SKULL Acu A-1 0.208   573181 114575 101493 81602 282505 155631 13106 
SKULL Acu A-2 0.206  784699 157421 113970 116738 339391 147183 35801 
SKULL Acu A-3 0.2114  78986 189464 34969 89294 28234 344909 8207 
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Bone Type: Animal: Mass (g):  DXM d3-DXM DXT d3-DXT DXT 150 d3-DXT 153 dmDXT 
SKULL Acu A-4 0.2026  251780 181755 29555 86355 18113 336996 1455 
SKULL Acu A-5 0.1998   1018929 152349 119577 177430 509390 186575 60567 
SCAPULA Acu A-1 0.1986   1249376 154054 n/a 320103 629983 322563 63053 
SCAPULA Acu A-2 0.1978  4951878 619299 n/a 723840 1522410 909889 172348 
SCAPULA Acu A-3 0.1914  207664 580031 174588 282793 88861 636992 22508 
SCAPULA Acu A-4 0.2113  1350696 262835 n/a 311795 141005 174843 48066 
SCAPULA Acu A-5 0.2016   754332 89911 138743 285034 458481 446409 113540 
BLOOD Acu A-1 0.25   135366 139258 21194 37940 14524 92825 0 
BLOOD Acu A-2 0.25  95136 93494 38949 43776 23671 88389 0 
BLOOD Acu A-3 0.25  208053 126661 75534 39417 57159 109329 0 
BLOOD Acu A-4 0.25  n/a n/a n/a n/a n/a n/a n/a 
BLOOD Acu A-5 0.25   184582 96583 24461 14729 26957 73213 0 
VERT Acu B-1 0.2098   865708 302552 196605 259389 274661 349234 142246 
VERT Acu B-2 0.2134  1196231 291283 241133 305102 363508 318474 300999 
VERT Acu B-3 0.2093  1113701 283265 225557 261721 296580 359569 282985 
VERT Acu B-4 0.2144  553159 219478 211559 242253 286562 328965 157631 
VERT Acu B-5 0.2098   1361103 550570 1431363 587629 n/a n/a 363373 
FEMUR Acu B-1 0.2153   1525833 213460 185634 230710 287170 425702 23371 
FEMUR Acu B-2 0.2069  1107747 299408 209514 341588 301016 517806 25608 
FEMUR Acu B-3 0.2152  587507 213242 25603 211804 64204 281332 945 
FEMUR Acu B-4 0.203  1693874 393745 241555 351557 331523 621697 21595 
FEMUR Acu B-5 0.2057   3660702 445623 1444719 471938 1883994 820923 194274 
RIB Acu B-1 0.2094   656936 141693 122643 134498 327790 285414 54594 
RIB Acu B-2 0.2146  1182467 244346 723675 265236 1298916 624451 134235 
RIB Acu B-3 0.2069  603789 270080 n/a 261705 182497 467891 71558 
RIB Acu B-4 0.1965  622771 245645 214521 290359 349157 563360 102566 
RIB Acu B-5 0.2088   4319499 463922 2002519 584577 3214070 977086 424249 
TIBIA Acu B-1 0.2083   1257227 216983 137996 239464 186983 430489 n/a 
TIBIA Acu B-2 0.2089  1848061 269575 n/a 276860 280389 439671 40061 
 
 
80 
 
Bone Type: Animal: Mass (g):  DXM d3-DXM DXT d3-DXT DXT 150 d3-DXT 153 dmDXT 
TIBIA Acu B-3 0.1995  555707 196259 n/a 175181 49921 279424 n/a 
TIBIA Acu B-4 0.2057  681325 201498 n/a 164086 119839 277699 n/a 
TIBIA Acu B-5 0.2048   622016 220892 n/a 228761 130053 306632 n/a 
PELVIS Acu B-1 0.2093   1005620 617426 n/a 404585 1109819 600458 98473 
PELVIS Acu B-2 0.2152  948966 690394 n/a 690225 700001 649111 133323 
PELVIS Acu B-3 0.2084  731166 250231 n/a 606255 235496 509894 76469 
PELVIS Acu B-4 0.2068  666907 318844 n/a 367222 998584 598571 60791 
PELVIS Acu B-5 0.2057   4875872 575259 n/a n/a 975948 1128382 141866 
SKULL Acu B-1 0.2135   674648 149632 n/a 389322 234764 305448 92051 
SKULL Acu B-2 0.2124  669373 120002 69581 165690 295042 116372 46719 
SKULL Acu B-3 0.2081  197347 181077 59519 71287 98835 218002 22055 
SKULL Acu B-4 0.2093  1357662 316213 46206 164369 112151 216461 22400 
SKULL Acu B-5 0.2113   1011550 214585 n/a 516566 611561 437150 135079 
SCAPULA Acu B-1 0.1917   875039 643986 n/a 189461 648223 405892 42122 
SCAPULA Acu B-2 0.1978  929246 362563 n/a 503424 n/a 750788 169675 
SCAPULA Acu B-3 0.2078  284271 312654 n/a 91792 80099 434066 2391 
SCAPULA Acu B-4 0.2019  823891 228258 64117 415567 337332 274521 64333 
SCAPULA Acu B-5 0.2076   1203727 166809 175437 374032 673663 275812 36499 
BLOOD Acu B-1 0.25   128071 113298 47431 42803 33575 92050 352 
BLOOD Acu B-2 0.25  38300 53651 15616 42525 16666 79323 408 
BLOOD Acu B-3 0.25  165734 104535 24597 47844 22031 83405 345 
BLOOD Acu B-4 0.25  254293 145460 90915 46948 56647 132452 716 
BLOOD Acu B-5 0.25   128824 83354 21920 25198 17778 61303 297 
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Appendix III: 
Mass Normalized Drug Responses 
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Table A3.1 Mass Normalized Response Ratios (RR/m) and Metabolite-Parent Ratios (DXT/DXM)  
Sample: A DXM RR/m: B DXM RR/m: A 150 DXT RR/m: B 150 DXT RR/m: A DXT/DXM: B DXT/DXM: 
VERT 1 23.141 13.638 4.930 3.749 0.213 0.275 
VERT 2 33.980 19.244 6.461 5.349 0.190 0.278 
VERT 3 8.370 18.785 1.816 3.941 0.217 0.210 
VERT 4 14.617 11.755 0.891 4.063 0.061 0.346 
VERT 5 33.007 11.783 11.238 n/a 0.340 n/a 
FEMUR 1 11.521 33.201 1.640 3.133 0.142 0.094 
FEMUR 2 13.146 17.882 1.417 2.810 0.108 0.157 
FEMUR 3 7.548 12.803 1.691 1.060 0.224 0.083 
FEMUR 4 14.812 21.192 1.074 2.627 0.073 0.124 
FEMUR 5 15.563 39.936 2.120 11.157 0.136 0.279 
RIB 1 26.308 22.141 4.061 5.485 0.154 0.248 
RIB 2 41.277 22.550 7.641 9.693 0.185 0.430 
RIB 3 3.667 10.805 0.722 1.885 0.197 0.174 
RIB 4 18.294 12.902 0.457 3.154 0.025 0.244 
RIB 5 28.832 44.592 8.914 15.754 0.309 0.353 
TIBIA 1 32.744 27.816 3.550 2.085 0.108 0.075 
TIBIA 2 18.243 32.817 2.531 3.053 0.139 0.093 
TIBIA 3 15.897 14.193 2.023 0.896 0.127 0.063 
TIBIA 4 30.082 16.438 1.041 2.098 0.035 0.128 
TIBIA 5 22.579 13.750 2.373 2.071 0.105 0.151 
PELVIS 1 22.585 7.782 4.905 8.831 0.217 1.135 
PELVIS 2 13.310 6.387 1.974 5.011 0.148 0.785 
PELVIS 3 7.778 14.021 1.953 2.216 0.251 0.158 
PELVIS 4 6.160 10.114 0.400 8.067 0.065 0.798 
PELVIS 5 32.043 41.205 8.247 4.205 0.257 0.102 
SKULL 1  24.051 21.118 8.727 3.600 0.363 0.170 
SKULL 2 24.198 26.262 11.194 11.937 0.463 0.455 
SKULL 3 1.972 5.237 0.387 2.179 0.196 0.416 
SKULL 4 6.837 20.514 0.265 2.475 0.039 0.121 
SKULL 5 33.474 22.309 13.665 6.621 0.408 0.297 
SCAPULA 1 40.836 7.088 9.834 8.331 0.241 1.175 
SCAPULA 2 40.424 12.957 8.459 n/a 0.209 n/a 
SCAPULA 3 1.871 4.375 0.729 0.896 0.390 0.205 
SCAPULA 4 24.321 17.878 3.817 6.086 0.157 0.340 
SCAPULA 5 41.616 34.760 5.094 11.765 0.122 0.338 
BLOOD 1 3.888 4.522 0.626 1.459 0.161 0.323 
BLOOD 2 4.070 2.855 1.071 0.840 0.263 0.294 
BLOOD 3 6.570 6.342 2.091 1.057 0.318 0.167 
BLOOD 4  6.993  1.711  0.245 
BLOOD 5 7.644 6.182 1.473 1.160 0.193 0.188 
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Appendix IV: 
Validation Standard Curves 
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Table A4.1 Standard Curve 1 Drug Responses 
Concentration 
(ng/ml) DXT d3-DXT DXM d3-DXM dmDXT DXT 150 d3-DXT 153 
0 0 0 394 0 0 5687 1111 
0 877 135 1687 0 0 4090 1611 
0 388 140 1473 81 0 4495 1803 
10 4427 121671 2244 97637 0 23389 244684 
10 7728 171565 4680 126162 0 31677 353911 
10 44438 169235 31861 123704 0 75033 337419 
25 19604 174316 8910 108813 0 41216 280976 
25 18867 152076 7101 102844 0 47686 270563 
25 24917 152573 14613 101628 0 38959 254931 
50 46511 164233 23963 102360 0 75679 260418 
50 51969 194090 24548 129328 0 70687 266819 
50 30863 113679 14840 95637 0 63071 214889 
100 88658 136700 46823 109248 0 135488 297753 
100 94170 159086 43977 106175 0 152676 268988 
100 101168 180809 46615 117791 0 159658 319484 
250 174719 113975 78542 82968 0 291453 240287 
250 223201 140430 90565 93734 0 281794 248972 
250 234216 166436 130816 110495 0 260032 271478 
500 451835 153125 210091 98773 219 626177 321177 
500 399882 145206 215725 104349 303 662158 299613 
500 373497 111409 208405 100168 205 534736 253112 
1000 829825 156422 455084 113519 1080 1386060 389285 
1000 780260 163519 435695 117842 10251 1319385 285520 
1000 817504 159400 506047 123442 14794 1342692 389938 
2000 1602285 192562 1376784 167206 31855 2108231 458873 
2000 3026665 295542 2470394 250962 45509 2733563 570074 
2000 2417366 254196 2416984 220418 50562 2541760 535887 
Accuracy x1 371284 175937 200992 156196 2367 642230 396684 
Accuracy x2 278692 159792 173199 169379 6015 474079 303067 
Accuracy x3 280347 144099 181945 155517 3139 527920 308742 
Accuracy y1 1174820 223524 841512 184641 14807 1900270 494284 
Accuracy y2 766519 142489 560621 121849 23075 1291052 343141 
Accuracy y3 1028406 194662 1157229 224932 31094 1423304 413048 
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Table A4.2 Standard Curve 2 Drug Responses 
Concentration 
(ng/ml) DXT d3-DXT DXM d3-DXM dmDXT DXT 150 d3-DXT 153 
0 0 0 0 0 0 8244 899 
0 1774 329 2431 92 0 6615 1778 
0 968 225 2289 106 0 5267 3073 
10 12246 131734 13537 162972 0 34738 267900 
10 10304 107071 8405 113281 0 26408 255517 
10 9966 145312 8991 132745 0 31427 292137 
25 26368 114964 20127 138505 0 57003 277072 
25 23369 125508 16305 130527 0 60151 256891 
25 23331 139067 19047 173171 0 68584 311966 
50 51129 141972 29414 109026 0 123315 324374 
50 40514 130279 38278 170136 0 103811 280673 
50 18237 92162 21976 128793 0 55193 199040 
100 90401 115981 51484 125349 0 187097 283745 
100 77653 116740 56887 127487 0 165013 254392 
100 83566 111292 48578 117924 0 167349 259589 
250 197454 139036 194195 160434 0 423121 292854 
250 207147 187564 228270 209423 0 410244 295145 
250 230316 186016 257508 235360 0 444686 285659 
500 392762 186983 463704 182028 1504 763672 377694 
500 468192 190652 478911 223572 4549 1019863 424045 
500 414995 172525 479045 227297 7426 721886 324605 
1000 677407 170069 760177 176095 9476 856730 298163 
1000 1991500 344478 1934879 359235 14279 2431301 704597 
1000 952860 204775 1063834 220655 10858 1300169 396997 
2000 3542259 358676 2690369 294911 45139 6095702 1138312 
2000 3368761 330494 2122312 276730 56013 5683214 948383 
2000 3574607 322280 2405499 267962 50891 5792391 904219 
Accuracy x1 116637 182333 123902 209312 0 242388 378260 
Accuracy x2 113260 242617 136297 251269 0 264976 390579 
Accuracy x3 103922 163503 102276 219567 0 210314 307656 
Accuracy y1 1209777 227450 1352695 235455 8764 1756022 515378 
Accuracy y2 2799497 387554 2153159 361511 19797 3005863 755312 
Accuracy y3 3016189 459478 2270787 404953 24650 4663484 1013363 
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Table A4.3 Standard Curve 3 Drug Responses 
Concentration 
(ng/ml) DXT d3-DXT DXM d3-DXM dmDXT DXT 150 d3-DXT 153 
0 1352 0 1456 0 0 4018 774 
0 0 0 144 0 0 1960 325 
0 497 0 1702 0 0 1661 574 
10 4311 87174 5195 64611 0 13286 186898 
10 6988 131067 5563 86962 0 16627 223275 
10 5727 147143 3947 81670 0 20403 264085 
25 15251 131888 8701 88465 0 33459 257979 
25 13892 103595 12074 82662 0 28316 205080 
25 29804 207089 13712 112892 0 54397 397168 
50 20699 75158 17362 69511 0 40320 141403 
50 29211 102029 14308 75453 0 57597 230979 
50 33270 145055 17481 85770 0 71410 278860 
100 116716 185008 69755 141245 0 208634 366115 
100 78941 145392 44273 93073 0 131310 269172 
100 127150 210470 61208 115537 0 158846 392287 
250 252339 186298 88684 68311 0 361940 350662 
250 215377 155115 94303 84213 0 364232 324706 
250 146685 129851 76485 88185 0 275162 282124 
500 432231 190991 148804 71494 11341 589598 323825 
500 481960 194952 177429 92562 4301 863055 432416 
500 529367 168612 236811 105221 9654 836294 401579 
1000 786400 197729 227195 63124 18607 1524491 448451 
1000 1101798 245721 283209 80687 39287 1725261 602362 
1000 848796 211121 359819 85421 33879 1671713 511183 
2000 1858750 250052 397295 56985 85220 2514408 592072 
2000 1693812 216401 492005 62400 59660 2196732 505445 
2000 2027298 281467 444472 60203 85875 2551419 632008 
Accuracy x1 427901 310316 162759 160529 5424 749163 593437 
Accuracy x2 212262 159020 134210 107268 8644 389363 312332 
Accuracy x3 229064 188448 209572 167509 8641 491606 345108 
Accuracy y1 1191353 269335 662509 140624 30717 2227432 616866 
Accuracy y2 1324834 283035 403407 76545 41751 2334031 599565 
Accuracy y3 968830 202867 446069 86178 35145 1710484 472266 
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Table A4.4 Standard Curve Mean Relative Responses (RR) and Coefficient of Variance (CV%) 
 
Concentration 
(ng/ml) 
Mean DXT 
150 RR 
DXT-150 
CV(%) 
Mean DXT 
RR 
DXT 
CV(%) 
Mean 
DXM RR 
DXM 
CV(%) 
Mean 
dmDXT RR 
dmDXT 
CV(%) 
C
u
rv
e 
1
 
0 3.38 44.4 n/a n/a n/a n/a n/a n/a 
10 0.09 4.6 0.11 111.8 0.11 124.2 0 n/a 
25 0.16 9.8 0.13 20.0 0.10 40.7 0 n/a 
50 0.28 5.6 0.27 2.9 0.19 20.5 0 n/a 
100 0.51 11.2 0.60 7.5 0.41 4.0 0 n/a 
200 1.10 11.8 1.51 6.2 1.03 12.8 0 n/a 
500 2.09 6.3 3.02 10.1 2.09 1.5 0 19.0 
1000 3.87 16.7 5.07 5.4 3.94 5.4 0.07 78.6 
2000 4.71 2.2 9.36 10.4 9.68 14.2 0.20 12.7 
Accuracy X 1.63 4.5 1.93 9.5 1.16 11.4 0.02 44.9 
Accuracy Y 3.68 5.7 5.31 1.2 4.77 6.9 0.14 40.2 
C
u
rv
e 
2
 
0 4.87 79.3 n/a n/a n/a n/a n/a n/a 
10 0.11 12.4 0.09 17.6 0.07 10.3 0 n/a 
25 0.22 6.5 0.19 16.3 0.13 14.0 0 n/a 
50 0.34 16.5 0.34 10.4 0.25 12.8 0 n/a 
100 0.65 1.2 0.73 8.1 0.42 4.8 0 n/a 
200 1.46 5.8 1.25 12.6 1.13 6.0 0 n/a 
500 2.22 8.6 2.32 8.3 2.27 10.8 0.02 59.7 
1000 3.20 9.2 4.81 18.9 4.84 11.0 0.05 15.1 
2000 5.92 8.9 10.39 6.1 8.59 9.3 0.18 14.1 
Accuracy X 0.67 3.5 0.58 17.0 0.53 11.9 0 n/a 
Accuracy Y 4.00 15.0 6.37 15.2 5.77 3.0 0.05 24.1 
C
u
rv
e 
3
 
0 4.71 34.5 n/a n/a n/a n/a n/a n/a 
10 0.07 4.2 0.05 15.8 0.06 25.0 0 n/a 
25 0.13 3.4 0.13 10.9 0.12 19.6 0 n/a 
50 0.26 7.2 0.26 11.5 0.21 14.7 0 n/a 
100 0.49 16.9 0.59 7.6 0.50 5.5 0 n/a 
200 1.04 7.1 1.29 10.9 1.10 19.8 0 n/a 
500 1.97 6.8 2.62 17.4 2.08 8.0 0.10 57.0 
1000 3.18 8.8 4.16 6.8 3.77 10.1 0.39 24.5 
2000 4.21 3.7 7.49 4.2 7.41 6.2 1.29 22.7 
Accuracy X 1.31 7.5 1.31 6.5 1.17 11.7 0.06 42.7 
Accuracy Y 3.71 4.3 4.63 3.9 5.05 5.9 0.39 42.0 
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Figure A4.1 Standard Curves Validation Plots  
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Appendix V: 
Relative Humidity Sensor Validation 
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Figure A5.1 Saturated Binary Salt Solution Relative Humidity Measurements.  
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Appendix VI: 
Daily Decomposition Site Notes 
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Table A6.1 Site A Decomposition Site Daily Notes 
Date: Time: 
Stage of 
Decomposition: 
Insect 
Activity: Notes: 
08-Jul   Fresh Yes 
Rats appear fresh. No odor. 2-3 Green bottle flies 
present. 
09-Jul 
  
Morning Fresh Yes 
Rats are fresh.  Dark discolouration on open organs going 
from pink to brown.  A few bottle flies present. 
Evening Fresh/Bloat Yes 
Rats beginning to exhibit abdominal distention, bloat 
becoming evident.  A mild odor of decomposition noted. 
Bottle flies present. 
10-Jul 
  
Morning Bloat Yes 
Continued distention of abdomen and bloat. Bottle flies 
present. 
Noon Bloat Yes As above, odor more evident. 
11-Jul Morning Bloat/Active Yes 
Rats exhibit transition from bloat to active decay, open 
abdomens, bodies begin to flatten.  Bottle flies and 
maggots evident, a single Silphidae (carrion beetle) 
observed approaching carcasses. 
12-Jul Morning Bloat/Active Yes 
Some open rat carcasses with extensive maggot activity.  
Bottle flies and maggots most prevalent, decomposition 
appears to outpace Site B at this time. 
13-Jul Morning Active Yes 
Notable odor approaching site. Decomposition 
proceeding well, maggots less evident, perhaps moving 
into carcasses from open abdomens.  Maggots and small 
bottle flies present. 
14-Jul Morning Active Yes 
Odour noted approaching site, becoming stronger closer 
to rats.  Little fly activity, a few flies noted at site, 
maggots active but appearing in less numbers than 
previous visits.  Carcasses exhibit some early flattening 
and open abdomens.  Skin appearing dark brown.  
Transition from active to dry? 
15-Jul Morning Active Yes 
Odour noted 10 m from site, closer and less strong than 
previous two visits.  Little fly activity, maggot activity 
subdued, appears to have less maggots present in rats.  
Active to dry transition?   
16-Jul Morning Active Yes 
Decreased odor noted approaching site.  Little bug 
activity, a few bottle flies present. Remains are mostly 
open, late active (?) with brown skin sloughing some fur, 
mostly still white. 
17-Jul Morning Active Yes 
Little insect activity after rain yesterday.  Rats wet, 
beginning to appear dry/late active transition, odor noted 
when close to site. 
18-Jul Morning Active Yes Similar to previous day. 
19-Jul Morning Late Active Yes 
Rat remains are open, flattening somewhat; bottle flies 
and siliphidae beetles present.  Mild odor present at site.  
 
 
93 
 
Date: Time: 
Stage of 
Decomposition: 
Insect 
Activity: Notes: 
20-Jul Morning Late Active Yes 
A few flies at site, mild odor.  Rats are open and 
flattening, some ribs poking through. Late active/dry 
transition? 
21-Jul         
22-Jul Morning Late Active Yes 
Beetles noted at site.  Faint odor, brown tissues and skin 
among bone tissue becoming exposed. 
23-Jul         
24-Jul         
25-Jul Afternoon Late Active/Dry No 
After hard rain earlier today, no observed insect activity.  
Rats wetted by precipitation, condition appearing late 
active/dry; some partial skeletonization, some soft 
tissues remain besides fragile appearing skin. 
26-Jul Morning Late Active/Dry Yes 
Some small “cheese skipper” and bottle flies with 
segmented black insects.  Body conditions are as previous 
day, flattening, with some exposed bone tissue 
27-Jul Morning Dry Yes 
Cheese skipper and black, segmented insects present.  
Bodies appearing more flat, bones more exposed; some 
skin and muscle tissues present.  Hot day, 31° today, 34° 
forecasted tomorrow 
28-Jul Morning Dry Yes 
Remains are flattening, partially skeletonized remains are 
present; exposed bone tissues and skin, some other 
tissue remains present.  A few “cheese skipper” flies and 
segmented bugs present at site. 
29-Jul Morning Dry No 
Flattening remains appear transitioning more fully into 
dry.  No observed insect activity. 
30-Jul       RATS COLLECTED 
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Table A6.2 Site B Decomposition Site Daily Notes 
Date: Time: 
Stage of 
Decomposition: 
Insect 
Activity: Notes: 
08-Jul   Fresh Yes Rats are fresh, no odor. 1 green bottle fly present. 
09-Jul 
  
Morning Fresh/Bloat Yes 
Rats appear generally fresh, exhibit beginning stages of 
bloat with presentation of some abdominal distension.  
Many bottle flies present, audible hum of activity noted 
approaching the site. 
Evening Bloat Yes 
Bloat is now evident, distension of carcasses greater than 
at Site A.  Decomposition odor is noted. 
10-Jul 
  
Morning Bloat Yes 
Greater degree of abdominal distension than in Site A, 
bottle fly activity greater than at Site A, as noted above. 
Noon Bloat Yes 
Swollen, balloon-like abdomens, numerous bottle flies 
and maggots present in open abdomen of Repeated #1 
11-Jul Morning Bloat/Active Yes 
Transition from Bloat to Active, some open sides on rat 
carcases as bodies begin to open and flatten.  Strong odor 
noted at site. 
12-Jul Morning Blot/Active Yes 
Some open rat carcasses with extensive maggot activity.  
Bottle flies and maggots most prevalent. Site B 
decomposition appears to lag Site A at this time, reversing 
initial appearance with fewer rats transitioning to Active 
appearance, some remaining in full bloat. 
13-Jul Morning Active Yes 
Odor is less notable than during past visits.  Bottle flies 
and maggots are present.  Rats central within the cage 
appear to decompose faster, active decay with open, 
flattening carcasses.  Rats on margins appear delayed, 
stagnant in bloat… drier conditions? Hidden maggots? 
14-Jul Morning Active Yes 
Little odor at site.  Very little fly activity, only a couple of 
small bottle flies identified.  Maggot activity seen, but less 
than during previous visits.  Rats central in cage open 
carcasses, losing hair, skin appearing brown.  Rats on 
margins appear behind in decomposition. 
15-Jul Morning Late Active Yes 
Odor subdued, noted only 2-3 m upwind of site.  Little fly 
activity, maggots present but less prevalent than earlier 
visits.  Central rats are open, skin losing fur appearing 
dark brown and leathery.  Rats on margins of cage appear 
“fresher”, white fur, carcasses appear more competent, 
lacking open abdomens and flattening of central rats. 
16-Jul Morning Late Active n/a 
Carcasses beginning to appear to dry; brown, leathery 
skin with muscle tissue present.  Most rats appear late 
active to dry. 
17-Jul Morning Late Active/Dry Yes 
A few bottle flies present, 1 large sarcophagidae seen.  
Rats wet from previous days precipitation, appear late 
active/dry, skin drawn and leathery, some rats competent 
while others open, subject to more early insect activity? 
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Date: Time: 
Stage of 
Decomposition: 
Insect 
Activity: Notes: 
18-Jul Morning Late Active/Dry Yes similar to previous day 
19-Jul Morning Late Active/Dry Yes 
flies audible at site, flesh flies among bottle flies present. 
Remains appear to be drying, little insect and no active 
maggots seen. 
20-Jul Morning Dry Yes 
Little fly activity at site. Carcasses more competent than 
Site A, maggot activity seems to have ceased w/in last few 
days; dry skin, loss of fur, leathery remains over partially 
decomposed and more complete remains. 
21-Jul         
22-Jul Morning Dry  Yes 
Numerous small to medium bottle flies at scene.  Odor 
down wind, more evident than at Site A today.  Skin 
appearing dry, from brown to greyish white in colour.  
Brown tissue remains on remains which appear more 
whole than at Site A 
23-Jul         
24-Jul         
25-Jul Afternoon Dry No 
As site A, wetted by precip; bodies more competent than 
other site.  No observed insect activity. 
26-Jul Morning Dry Yes 
A few bottle flies and a carrion beetle observed. Bodies 
remain pseudo-competent, skin losing fur, skin appearing 
brownish to light grey. 
27-Jul Morning Dry Yes 
Hot at site. Only 2 small bottle flies observed.  Remains 
appearing mummified almost, competent to partially 
decomposed.  Those exhibiting more advanced 
decomposition appearing flatter than other, more whole 
rats. 
28-Jul Morning Dry No 
No observed insect activity. Papery appearing skin, some 
"partial skeletonization" with exposed ribs and other 
bone tissues, generally remains are more competent with 
near to complete appearing remains. 
29-Jul Morning Dry No 
No insect activity observed (1 flesh eater fly seen at 
leaving of site on cage margin) Dry, papery skin appearing 
whitish brown, condition of remains indicative of less 
insect activity past bloat(?) than at Site A; remains 
partially mummified/desiccated? 
30-Jul       RATS COLLECTED 
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